Regulation of the Huntingtin Interacting Protein 1 (HIP1) Gene. by Graves, Chiron Wesley
REGULATION OF THE HUNTINGTIN INTERACTING PROTEIN 1 (HIP1) 
GENE 
by 
Chiron Wesley Graves 
 
A dissertation submitted in partial fulfillment 
of the requirements of the degree of  
Doctor of Philosophy 
(Cellular and Molecular Biology) 









Associate Professor Theodora S. Ross, Chair 
Professor Andrzej A. Dlugosz 
Associate Professor John V. Moran 
Assistant Professor Peter C. Lucas 








To Charles Edward Graves, 






First off, I want to thank my thesis advisor, Theodora S. Ross. She provided me 
with the encouragement and the intellectual freedom to pursue this project and her 
patience with me as I “found my way” has been instrumental in my development as a 
scientist and a scholar. Most importantly, her scientific enthusiasm and sense of humor 
was a joy to be around. I would also like to thank my thesis committee members, Andrzej 
A. Dlugosz, John V. Moran, Peter C. Lucas and Joann Sekiguchi for their time and 
guidance throughout this project. 
I would like to thank fellow Ross labmates, Steven T. Philips, Sarah V. Bradley, 
Katherine I. Oravecz-Wilson, Lina Li and Alice Gauvin, for their contributions to chapter 
2 of this thesis, which was published in modified form: 
Graves, C. W., Philips, S. T., et al. (2008) “Use of a cryptic splice site for the 
expression of huntingtin interacting protein 1 in select normal and neoplastic 
tissues.” Cancer Research 68(4): 1064-1073. 
 
Additionally, I would like to thank them, as well as Heather Ames and Brendan 
Crawford, for their friendship, additional contributions to other parts of this thesis and 
support throughout this journey. Thanks to the Day lab for equipment use, cells, samples 
reagents and friendship when I needed them. Thanks to the Zhang lab for the use of their 
quantitative PCR machine. Thanks to the Robbins and Lucas labs for allowing me to use 
their luminometers. Thanks to the Keller lab for allowing me to use their Nanodrop. 
Thanks to the Dr. Miriam Meisler for her constructive intellectual input and for critical 
review of the manuscript mentioned above. I would also like to acknowledge the 
University of Michigan DNA Sequencing Core, which provided excellent sequencing 
data. 
 Of course my thesis research would not be possible without funding. I would like 
to thank all the funding sources that allowed me to pursue my research. They include the 
iv 
 
following: The University of Michigan Cancer Biology training grant, the Rackham 
Merit Scholar fellowship and the Program in Biomedical Sciences predoctoral 
fellowship. I would also like to thank the administrators associated with these funding 
sources. Special thanks go to LaCheryl Wicker for her friendship and support in dealing 
with the multiple issues, such as not getting paid, associated with being a graduate 
student. Thanks to Tiffany Portes-Stone for her friendship and support, both of which 
have been extremely value along the way.  
Thanks to Dr. Jessica Schwartz and the Cellular and Molecular Biology (CMB) 
Graduate Program for providing me with the intellectual environment and support to 
develop as a scientist and future academic scholar. Thanks to CMB administrative 
assistants, Claire Kolman and Cathy Mitchell for their support in preparing for seminars 
and recruiting weekends. It was a pleasure to work with both of you. I would also like to 
thank a few other programs and organizations that played a small but instrumental role in 
my initial development as a doctoral student. Thanks to the Summer Institute for allowing 
me to began my doctoral pursuit in the summer prior to my enrollment as a student. The 
opportunity allowed me to get back into the flow of scientific research after having been 
away for over 5 years. Thanks to the Association of Multicultural Scientists for providing 
me with a support group consisting of scientists who shared common experiences with 
me. Thanks to the Graduate Program in Immunology for providing me with the 
intellectual base for jumpstarting my doctoral studies 
Most importantly, I would like to thank all my family and friends for their 
unconditional love and support of me through the good and bad times. Very special 
thanks to the five most important women in my life. To my mother, JoAnn L. Graves, for 
all the sacrifices she has made and all the heartache she has endured because of me. I 
would not be here, literally and figuratively, if it were not for her. To my wife, Folake, 
for allowing me to pursue my dream after our family was established and for “holding 
down the fort” when I was gone. I know it’s been tough, but we’re almost there. To my 
sister, Dr. Shanna L. Graves, the first in our family to earn a PhD. It’s not often that a 
younger sibling serves as a role model for the older sibling but you have definitely been 
mine. The strength you exhibited during your pursuit gave me the strength and courage to 
continue pursuing mine. To my two girls, Kyla and Kharis for their patience with me 
v 
 
when we couldn’t do things “as a family” because I was busy working in the lab. I hope I 
can still make it up to you.  
Finally, I would like to thank my father, the late Charles E. Graves, who served as 
the best role model anyone could ever wish for. He taught me how to be a father and a 





TABLE OF CONTENTS 
DEDICATION................................................................................................................... ii 
ACKNOWLEDGEMENTS ............................................................................................ iii 
LIST OF FIGURES ....................................................................................................... viii 
ABSTRACT ....................................................................................................................... x 
CHAPTER 1 ...................................................................................................................... 1 
INTRODUCTION .............................................................................................. 1 
HIP1 and Endocytosis ..................................................................................... 2 
HIP1 and Apoptosis ........................................................................................ 2 
HIP1 as a Pro-Survival Protein ....................................................................... 3 
HIP1 and Cancer ............................................................................................. 4 
Complex Phenotypes of Hip1 Loss of Function Mice .................................... 5 
A Case for Multiple HIP1 Isoforms ................................................................ 8 
CHAPTER 2 .................................................................................................................... 12 
USE OF A CRYPTIC SPLICE SITE FOR THE EXPRESSION OF 
HUNTINGTIN INTERACTING PROTEIN 1 IN SELECT NORMAL AND 
NEOPLASTIC TISSUES ............................................................................................. 12 
Summary ....................................................................................................... 12 
Introduction ................................................................................................... 13 
Materials and Methods .................................................................................. 14 
Results ........................................................................................................... 21 
Discussion ..................................................................................................... 29 
vii 
 
CHAPTER 3 .................................................................................................................... 44 
ALTERNATIVE HIP1 TRANSCRIPTS IN MOUSE AND HUMAN CELLS 
MAY ENCODE DIFFERENT HIP1 ISOFORMS ....................................................... 44 
Summary ....................................................................................................... 44 
Introduction ................................................................................................... 44 
Materials and Methods .................................................................................. 46 
Results ........................................................................................................... 49 
Discussion ..................................................................................................... 55 
CHAPTER 4 .................................................................................................................... 73 
ANALYSIS OF THE HIP1A PROMOTER ..................................................... 73 
Summary ....................................................................................................... 73 
Introduction ................................................................................................... 73 
Materials and Methods .................................................................................. 75 
Results ........................................................................................................... 79 
Discussion ..................................................................................................... 83 
CHAPTER 5 .................................................................................................................... 95 
CONCLUSION ................................................................................................. 95 
Partially functional HIP1 product suggests multiple isoforms with separate 
cellular functions ....................................................................................................... 95 
Alternative transcripts may code for different isoforms ............................... 96 
Transcriptional regulation of HIP1A is complex .......................................... 98 
The future of HIP1 ........................................................................................ 99 





LIST OF FIGURES 
Figure 1.1: Diagram of the HIP1 protein. ......................................................................... 10 
Figure 1.2: Comparison of the 5’ end of the HIP1 gene in human and mouse. ................ 10 
Figure 1.3: Diagram of the 3’end of the HIP1 gene. ........................................................ 11 
Figure 2.1:  Amino acid sequence of the HIP1 ANTH domain and schematic diagram of 
the HIP1 domain structure. ............................................................................................... 31 
Figure 2.2: Tumorigenesis in MMTV-myc mice in the absence of HIP1. ....................... 32 
Figure 2.3: Breast tumorigenesis in the presence of the Hip1Δ3-5 allele......................... 33 
Figure 2.4: Tumor incidence in mice with Hip1Δ3-5 and Hip1null alleles. ..................... 34 
Figure 2.5: TRAMP mice on different Hip1 mutant backgrounds. .................................. 35 
Figure 2.6: Expression of Hip1 sequences in Hip1Δ3-5 mice .......................................... 36 
Figure 2.7: Partial Hip1Δ3-5 cDNA sequence alignment with wild type mouse Hip1 
cDNA. ............................................................................................................................... 37 
Figure 2.8: Expression patterns of the 3-5insAG mRNA and its putative protein product.
........................................................................................................................................... 38 
Figure 2.9: HIP1 Δ3-5/insAG 106 kDa protein is present in mouse embryonic brain and 
fibroblasts. ......................................................................................................................... 39 
Figure 2.10: Conditional cre-mediated recombination of the floxed Hip1 allel leads to 
either HIP1 deficiency or epxression of the truncated product depending on tissue 
analyzed ............................................................................................................................ 40 
Figure 2.11: HIP1 3-5insAG association with clathrin, AP2, EGFR and lipids. ............ 42 
Figure 2.12: Comparison of lipid binding specificity and relative affinity GST-
5’HIP1/Δ3-5 and GST-5’HIP1 using PIP strips. .............................................................. 43 
Figure 3.1: Diagram of alternative Hip1 transcripts in mouse. ......................................... 60 
Figure 3.2: Standard curve for mouse Hip1a and Hip1b transcript analysis. ................... 61 
Figure 3.3: Absolute Hip1 transcript levels in undifferentiated RAW cells. .................... 61 
ix 
 
Figure 3.4: Relative Hip1a and Hip1b transcript levels in various mouse tissues. .......... 62 
Figure 3.5: Western blot analysis of mouse tissues .......................................................... 62 
Figure 3.6: RAW cell differentiation into RAW-OC results in an induction of higher 
molecular weight protein .................................................................................................. 63 
Figure 3.7: Relative Hip1 transcript levels in differentiated RAW-OC cells ................... 64 
Figure 3.8: Ratio of Hip1a to Hip1b transcript levels in immortalized and non-
immortalized mouse embryonic fibroblasts (MEFs) ........................................................ 65 
Figure 3.9: Standard curve for human HIP1A and HIP1B transcript analysis. ................ 66 
Figure 3.10: Absolute HIP1 transcript levels in HEK 293T cells .................................... 67 
Figure 3.11: Ratios of HIP1A to HIP1B in selected cancer cell lines .............................. 68 
Figure 3.12: Exogenous expression of HIP1B AUG mutants in HEK 293T cells. .......... 69 
Figure 3.13: Putative open reading frames (ORFs) in HIP1B transcript. ......................... 70 
Figure 3.14: Alignment of predicted protein sequences. .................................................. 71 
Figure 3:15: Western blot analysis of mutant Hip1b-transfected cells. ............................ 72 
Figure 4.1: Human HIP1A promoter sequence. ................................................................ 85 
Figure 4.2: Diagram of various promoter constructs. ....................................................... 86 
Figure 4.3: Human HIP1A promoter activity in 293T cells. ............................................ 86 
Figure 4.4: Human HIP1A promoter activity in both HEK 293T and K562 cells. ........... 87 
Figure 4.5: Diagram of the “region of interest” deletion mutant construct. ..................... 88 
Figure 4.6: Promoter activity of -181/-108 deletion mutant in HEK 293T and K562 cells.
........................................................................................................................................... 88 
Figure 4.7: Diagram of promoter constructs with κB sites. .............................................. 89 
Figure 4.8: Human HIP1A promoter activity in HEK 293T cells following NFκB 
induction with TNF . ....................................................................................................... 90 
Figure 4.9: Diagram of the NFκB mutant construct. ........................................................ 91 
Figure 4.10: NFκB mutant promoter activity in HEK 293T cells following NFκB 
induction with TNF . ....................................................................................................... 91 
Figure 4.11: Human HIP1A promoter activity in RAW 264.7 cells following NFκB 
induction with RANKL..................................................................................................... 92 
Figure 4.12: HIP1A transcript levels following NFκB induction. .................................... 93 





Huntingtin Interacting Protein (HIP1) is a multi-domain clathrin binding protein 
thought to play a role in receptor-mediated endocytosis.  HIP1 contains an adaptor AP180 
N-terminal homology (ANTH) inositol lipid-binding domain, specific to endocytic 
proteins, as well as clathrin- , AP2- and actin-binding motifs.  Loss of Hip1 and its only 
known mammalian relative Hip1-related (Hip1r) leads to spinal defects, testicular 
degeneration, cataracts, adult weight loss, and early death in mice, indicating that the 
Hip1 family is necessary for the maintenance of normal adult tissues.   
There are conflicting reports concerning the role of HIP1 in cellular survival and 
proliferation. Our laboratory has found that HIP1 promotes cellular survival and 
transformation and therefore is involved in supporting tumorigenesis. Others have 
suggested that HIP1 plays a role in promoting apoptosis and this activity is the cause of 
neuronal cell death in Huntington’s disease patients. This conflict raises the possibility 
that multiple isoforms of HIP1 exist and these isoforms have contrasting activities. 
Indeed, I have observed multiple isoforms of HIP1 using many different anti-HIP1 
antibodies and western blot analysis in both mouse and human tissues.   
To understand the regulation of HIP1 we have isolated its promoter and 
characterized it.  We have also evaluated the gene for alternative transcripts.  The HIP1 
gene is a complex 31-exon gene that spans approximately 250 Kb of DNA. This 
complexity is highlighted by our first attempt to generate a conditional knockout allele of 
Hip1.  Unexpectedly, we found expression of a mutant HIP1 protein in select tissues 
(lung, brain) due to use of a cryptic splice site. Additionally, we have identified and 
characterized two alternative Hip1 mRNA transcripts that comprise distinct first exons, 
designated Hip1a and Hip1b. These transcripts are present in human and mouse tissues 
and may encode for two HIP1 isoforms with distinct cellular functions. The findings 
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described in this thesis provide a foundation for expanding our current understanding of 






The Huntingtin Interacting Protein 1 (HIP1) is a fascinating protein with a history 
as diverse as its suggested roles in normal and aberrant cell biology. HIP1was initially 
discovered in 1997 by two independent labs through a yeast-two hybrid system [1, 2]. 
The “bait” used in both these studies was huntingtin (htt), the protein whose gene is 
mutated in Huntington’s disease. Understandably, subsequent studies have investigated 
the role of HIP1 in the pathology of Huntington’s disease [3, 4]. Various studies have 
also implicated HIP1 in cancer biology [5-11]. Perhaps the most universally-accepted 
role of HIP1 is that of its involvement in receptor-mediated endocytosis due in large part 
to its homology with the yeast endocytic protein, Sla2p. Yet one could easily argue that 
the role of HIP1 in normal biology remains elusive. Indeed, it is quite possible that HIP1 
may have multiple cellular functions. The fact that there are conflicting reports on HIP1 
involvement in apoptosis-mediated cell death [3, 4, 9] strongly suggests the existence of 
multiple isoforms of the protein, yet there have been no reports of multiple isoforms of 
the mammalian HIP1 protein to date. Most studies are directed towards deciphering a role 
for the HIP1 protein, rather than transcriptional and post-transcriptional regulation of the 
HIP1 gene. Given the sheer size and intriguing genomic structure of the HIP1 locus, the 
HIP1 gene is an excellent model for studies in transcriptional and post-transcriptional 
regulation. This chapter reviews the data demonstrating the ambivalent role of HIP1 as a 
pro-survival or pro-apoptotic protein. Additionally, we discuss effects of loss of Hip1 and 





HIP1 and Endocytosis 
There is considerable evidence suggesting that HIP1 is involved in receptor-
mediated endocytosis. HIP1 is a homologue of the yeast protein, Sla2p. Wesp and 
colleagues showed that Sla2p is required for endocytosis and actin dynamics and that the 
N-terminus of the protein was important for these functions [12]. Within this region of 
the protein is an AP180/CALM N-terminal homology domain (ANTH).  HIP1 also 
contains an ANTH domain (Figure 1.1). ENTH/ANTH domains have been found in 
several proteins with known involvement in clathrin-mediated vesicle trafficking [13]. 
The ENTH/ANTH domain-containing proteins have been reported to bind specifically to  
phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] and phosphatidylinositol-3,4,5-
triphosphate [PtdIns(3,4,5)P3] [14, 15]. However, Hyun and colleagues have shown that 
HIP1 preferentially binds to PtdIns(3,4)P2 and PtdIns(3,5)P2 [16]. This is significant 
given that PtdIns(3,4)P2 and PtdIns(3,5)P2 are enriched in early endosomes, whereas 
PtdIns(4,5)P2 is primarily found in the plasma membrane [17].  
In addition to an ANTH domain, HIP1 contains consensus binding sites for the 
endocytic adaptor protein AP2 (DPF motif) and clathrin heavy chain (LMDMD clathrin-
box motif) (Figure 1.1) and has been shown to associate directly with these proteins [18-
21]. The central helical domain of HIP1 has been shown to bind directly to the clathrin 
light chain and stimulate clathrin assembly in vitro [22, 23]. Mice that have lost HIP1 due 
to deletion of the Hip1 gene show diminished recruitment of HIP1-binding endocytic 
proteins to liposomes isolated from brain lysates as well as decreased AMPA receptor 
trafficking [24]. Indeed, there is strong convincing evidence demonstrating the role of 
HIP1 in endocytosis and most would agree with this role. However, there is disagreement 
in the field concerning additional roles of HIP1 is pro-survival or pro-apoptotic. There is 
evidence supporting both roles, which we will review next.  
HIP1 and Apoptosis 
Because HIP1 was initially identified through its interaction with huntingtin (htt), 
efforts have been made to determine if it plays a role in the pathology of Huntingtin’s 
disease. HIP1 is expressed at high levels in the central nervous system and colocalizes 




with wildtype htt than with mutant htt. Exogenous expression of HIP1 in neuronal and 
non-neuronal cells has been reported to induce apoptosis due in large part to a highly 
conserved phenylalanine at position 398 in a pseudo-death effector domain (pDED) [4]. 
Co-expression of a wildtype N-terminal htt with HIP1 reduced apoptotic activity. In this 
report, it was concluded that HIP1-mediated apoptosis occurred in a caspase-8 
independent fashion.  
A couple of years later, Gervais and colleagues reported that HIP1-mediated 
apoptosis occurred in collaboration with HIP1 protein interactor (HIPPI) [3]. Both 
proteins colocalize in the Golgi apparatus of neuronal NT2 cells and interact with each 
other. Both proteins contain a pDED and loss of this domain in either protein diminished 
their interaction with each other. However, HIPPI does not contain the essential Phe398 
in its pDED. When both proteins were co-expressed in 293T cells that stably expressed 
mutant htt their interaction was stronger than in cells stably expressing wildtype htt. 
Additionally, co-expression of HIP1 and HIPPI in both 293 and HeLa cells led to 
increased caspase 3 activity. In contrast to the earlier report by Hackam et al., HIP1-
mediated apoptosis in cooperation with HIPPI occurred in a caspase 8-dependent manner. 
The proposed model for HIP1-mediated apoptosis provided by Gervais et al. states that 
HIP1 is normally bound and sequestered by wildtype htt. When htt is mutated, HIP1 is 
freed and allowed to bind HIPPI, leading to a complex that sequesters procaspase 8 and 
activates it. Surprisingly, an explanation for the difference in apoptotic pathways 
activated in HIP1-mediated apoptosis was not discussed. 
HIP1 as a Pro-Survival Protein 
The HIP1 gene product was first implicated in cellular survival when Rao et al. 
reported that Hip1-deficient mice exhibit testicular degeneration due to apoptosis of 
postmeiotic spermatids [20]. The investigators observed testicular degeneration in Hip1
-/-
 
mice by hematoxylin and eosin staining as well as decreased numbers of spermatogenic 
precursors at various stages of development. Additionally, testicular tissue from HIP1-
deficient mice displayed more TUNEL-positive cells compared to control mice.  
Separately, Rao et al. demonstrated that exogenous expression of full length HIP1 
does not induce apoptosis [9]. However, exogenous expression of a HIP1 deletion mutant 




Apoptosis observed with this mutant was inhibited by a dominant-negative caspase-9 
mutant, suggesting use of the intrinsic apoptotic pathway. A year later, Rao and 
colleagues reported that full-length HIP1 has transforming abilities [8]. In this study, 
NIH/3T3 cells that were stably transfected with a full-length HIP1 cDNA construct under 
the control of either a long terminal repeat (LTR) or cytomegalovirus (CMV) promoter 
exhibited a transformed phenotype as determined by tumor formation in nude mice, 
anchorage-independent growth in soft agar and growth in low serum conditions. Indeed 
these data suggest that the full-length form of HIP1 is pro-survival and tumorigenic when 
exogenously expressed. These data also suggest the possibility of a second naturally-
occurring isoform, similar to the the HIP1-ΔE construct, that may be pro-apoptotic when 
aberrantly expressed.   
HIP1 and Cancer 
An initial connection between HIP1 and cancer was first reported by Ross et al. 
[10]. The HIP1 gene was identified as the chromosome 7 partner in a t(5;7)(q33; q11.2) 
translocation, which also involved the platelet-derived growth factor β receptor 
(PDGFβR) on chromosome 5, in a patient with chronic myelomonocytic leukemia 
(CMML). The result is a fusion protein, which contains all but the final 18 amino acids of 
the HIP1 protein fused to the transmembrane and tyrosine kinase domains of the 
PDGFβR. The fusion protein has constitutive tyrosine kinase activity and is capable of 
transforming the interleukin-3 (IL3)-dependent murine hematopoietic cell line, Ba/F3 
cells to IL3-independent growth [11].  
Since this initial discovery, evidence to bolster the connection between HIP1 and 
cancers has grown. Rao and colleagues observed that HIP1 is expressed at high levels in 
multiple cancers [9]. Of 53 cancer cell lines from the NCI60 group [25] derived from 
solid tumors of various tissue origins (breast, colon, kidney, lung, melanoma, ovarian and 
prostate), 50 of them expressed high levels of HIP1 by western blot analysis. They 
confirmed these data with immunohistochemical staining of primary human cancer tissue 
microarrays, which demonstrated moderate to high staining of HIP1 in most of the cancer 
types represented in the NCI60 cancer cell line panel. It is worth noting that HIP1 was 
undetectable in both normal colon and normal prostate epithelium. Additionally HIP1 




of HIP1 expression was observed in the benign prostate epithelium, intermediate 
expression levels were observed in precancerous prostate lesions and high levels were 
observed in metastatic prostate cancer. Furthermore, an analysis of linked clinical data for 
114 patients with prostate-confined cancer revealed that none of the cases with HIP1-
negative tumors relapsed after radical prostatectomy while 28% of the cases with HIP1-
positive tumors did. Finally, an analysis of tumors taken from the transgenic mouse 
model of prostate cancer (TRAMP) displayed high levels of HIP1 expression in 50% 
compared to benign tissue. Finally, the list of cancers in which HIP1 has been connected 
has expanded to include brain cancer [5] and both Hodgkin’s disease and non-Hodgkin’s 
lymphoma [7]. 
In addition to HIP1 serving as a prognostic marker in cancer, several pieces of 
data implicate HIP1 in promoting tumorigenesis. As mentioned earlier, stable exogenous 
expression of full-length HIP1 transforms fibroblasts [8]. The proposed mechanism of 
transformation was altered trafficking of receptor tyrosine kinases such as the epidermal 
growth factor (EGF) receptor, the fibroblast growth factor (FGF) receptor and the platelet 
derived growth factor (PDGF)-β receptor as the levels of these receptors were elevated in 
HIP1-transformed cells [8]. In 2004, Hyun et al. expanded on this hypothesis by 
reporting that exogenous expression of full-length HIP1 in 293T cells stabilizes the EGF 
receptor levels following stimulation with EGF [16]. In 2005, Bradley et al. expanded on 
the previously reported association between prostate cancer and HIP1 with the 
observation that tumor formation was reduced in TRAMP mice that lacked HIP1 
expression [6]. Additionally, they observed increased levels of anti-HIP1 antibodies in 
patients with prostate cancer, an observation that was also predictive. Given the scope of 
studies connecting HIP1 with cancer, it appears evident that HIP1 has a functional 
involvement in cancer. 
Complex Phenotypes of Hip1 Loss of Function Mice 
One of the most valuable scientific research tools for determining function of a 
particular gene is targeted deletion of the gene of interest in mice and extensive analysis 
of phenotypic abnormalities. This approach is particularly feasible when both the mouse 
and human proteins are highly conserved, as is the case with HIP1 (the mouse and human 




has been attempted by multiple laboratories using diverse targeting strategies [20, 24, 
26]. These studies have provided us with valuable insight yet the complexity of the 
different phenotypes has prevented complete resolution of the all-important question, 
“What does HIP1 do?” as we shall see below. 
The first knock-out of the Hip1 locus was reported in 2001 through targeted 
deletion of exons 2 through 8 [20]. As mentioned earlier, these mice exhibited testicular 
degeneration due to apoptosis of the postmeiotic spermatids. A couple of years later, 
Metzler et al. reported a separate Hip1 loss-of-function mouse. They used a promoter-
trap gene targeting strategy in which exon 8 and its adjacent intronic sequence was 
replaced with a SA-IRES-βGeo-pA cassette encoding a bifunctional lacZ-neomycin 
fusion protein. The resulting mice were born with normal Mendelian distribution and 
grow similar to wildtype mice early in their lives. However, approximately 12 weeks 
after birth these mice began to show growth retardation and “thoracolumbar kyphosis” 
with as secondary condition of “wasting, tremor and a gait ataxia”. The thoracolumbar 
kyphosis was observed as early as 9 months of age with greater than 85% of the mice 
demonstrating this phenotype by one year of age. A block in ligand-induced AMPA 
receptor internalization was also observed in the brain cells cultured from these mice. 
Interestingly, there were no observable defects in gross brain morphology despite the fact 
that HIP1 is highly expressed in this organ. 
In 2004, Oravecz-Wilson and colleagues reported two new independently 
generated mutant HIP1 mice [26]. One of the mutant mice was generated 
“serendipitously” by attempting to knock-in a human HIP1/PDGFβR fusion protein 
cDNA into the Hip1 locus. This resulted in a loss of normal HIP1 expression so the mice 
were studied as nulls (referred to as Hip1
null/null
). Similar to the mutant mice reported 
earlier by Metzler et al., these mice displayed degenerative spinal defects with 100% of 
the mice studied developing this phenotype after one year of age. Unlike the mutant mice 
reported on by Metzler et al., Hip1
null/null
 mice were born in significantly decreased 
numbers compared to expected Mendelian ratios, suggesting partial embryonic lethality. 
Additionally, Hip1
null/null
 mice were infertile (males only), developed cataracts, and 
exhibited stunted growth and hematopoietic abnormalities, including resistance to 5-




endocytic machinery were found in embryonic fibroblasts. Both spinal defects and 
growth abnormalities were accelerated when the only other known mammalian family 
member of Hip1, Hip1-related (Hip1r) was disrupted [27]. The spinal defects, growth 
defects and cataracts were rescued with heterologous expression of full-length HIP1, 
indicating that these phenotypes were indeed associated with a loss of Hip1 [28]. 
The second mutant mouse reported in the study (termed Hip1
Δ3-5/Δ3-5
 mice 
following recombination of the alleles) was generated by targeted and conditional 
deletion of exons 3 to 5 of the Hip1 locus [26]. Although these mice were not as 
extensively studied as Hip1
null/null
 mice, comparisons of the two mutant mice were made. 
Hip1
Δ3-5/Δ3-5
 mice were born at normal Mendelian ratios. Eighty percent of Hip1
Δ3-5/Δ3-5
 





mice were infertile, exhibited testicular degeneration and were also resistant to 5-FU 
treatment. No cataracts were observed in Hip1
Δ3-5/Δ3-5 
mice. The differences between 
these various targeted Hip1 mutants may be due to incomplete null status. Alternatively, 
some of the defects observed in the Hip1
null/null
 mice may be the result of disruption of 
Hip1-neighboring genes due to the presence of the neomycin selection cassette.  
Although HIP1 was discovered over 10 years ago, we know very little about the 
regulation of HIP1 gene expression. The HIP1 gene structure is complex. The mouse 
Hip1 gene maps on chromosome 5 at position 5qG2 in humans, and covers over 139 Kb. 
The human gene maps to chromosome 7 at position 7q11.23 and covers over 204 Kb. 
Both genes contain disproportionately large first introns relative to the rest of the gene 
(Figure 1.2). Intron 1 of the human HIP1 gene comprises over 139 Kb (roughly 68% of 
the gene) while intron 1 of the mouse Hip1 gene consists of over 89 Kb (about 64%). The 
existence of such a large intron suggests the possibility of an alternative promoter leading 
to expression of an additional transcript. Both human and mouse mRNA transcripts 
consist of 31 exons, which suggests the possibility of multiple HIP1 transcripts through 
alternative splicing. Large 3’ untranslated regions (3’ UTR) of over 6kb in both mouse 
and human (Figure 1.3) suggest additional regulatory mechanisms. Given this data it 





A Case for Multiple HIP1 Isoforms 
There is reason to believe multiple forms of HIP1 protein exist. The presence of 
multiple bands within the range of 100 to 120 kDa in western blot analysis of HIP1 
expression has been noted repeatedly in studies involving HIP1. Initially, Chopra et al 
reported the presence of alternative HIP1 transcripts following their 5’ rapid 
amplification of cDNA ends (RACE) analysis of human brain RNA [29]. These 
alternative transcripts differ at their 5’ ends and were attributed to alternative splicing of 
exons 1, 2 and 4 (labeled as HIP1-1) or exons 1, 3 and 4 (HIP1-2). Further 
characterization of these transcripts has not been performed to date.  
Recently Moores and colleagues identified two variant cDNA clones in 
Drosophila that have homology to HIP1 [30]. Sequence analysis of these clones revealed 
that the two variants have alternative first exons and an identical six core exons from 2 to 
7 followed by different transcriptional termination sites in a final eighth exon. The first 
clone (labeled CG10971-RA) represents a 3881-bp transcript with a predicted protein 
product of 1124 amino acids, including a complete ANTH domain (dubbed full-length 
Hip1). The second clone (CG10971-RB) represents a 3983-bp transcript and a predicted 
protein product of 1026 amino acids. Most notably, the predicted protein product does 
not include a complete ANTH domain (Hip1 ANTH). Excluded from the truncated 
ANTH domain are the consensus sequence of (K/G)A(T/I)X6(P/L/V)KXK(H/Y) 
necessary for lipid binding [31]. Interestingly, the two proteins display contrasting roles 
in neurogenesis. Full-length Hip1 decreased sensory bristle density, whereas 
Hip1 ANTH led to an increase in sensory bristle density. The authors conclude that plays 
a dual-regulatory role in neurogenesis based on the correlation between bristle density 
and the number of sensory neurons formed [32, 33]. The idea that Hip1 plays a dual-
regulatory role in development is an interesting one considering apoptosis plays a 
prominent role in early organism development and over-expression Hip1 that lacks the 
ANTH domain induces apoptosis. However, one would predict that Hip1 ANTH would 
decrease bristle density.  
As indicated earlier in this chapter, Rao et al. reported similar contrasting roles of 
a full-length human HIP1 construct and a mutated construct (HIP1 E), which lacks the 




percentage of apoptotic cells compared to exogenous expression with full-length HIP1. 
The increase in cell death observed was attributed to a “dominant-negative” behavior of 
the ANTH domain-lacking HIP1 protein. Although a transcript representing the mutated 
human construct has not been reported to date, this data does present an intriguing 
explanation for the contrasting reports the role of HIP1 in cellular survival versus its role 
as an inducer of apoptosis.  
The major focus of this thesis project is to investigate the existence of an 
additional HIP1 isoform primarily through examination of transcriptional and post-
transcriptional regulation of the HIP1 gene. In chapter 2, we began to explore the 
necessity of HIP1 in prostate and breast cancer using a conditional Hip1 knockout 
strategy. Unexpectedly we discovered a novel cryptic splice site in the Hip1 gene, which 
uses the rare U12 minor-class pathway to maintain expression of a partially functional 
protein [34]. Chapter 3 explores the possible expression of multiple HIP1 mRNA 
transcripts in both mouse and human and their potential connection with the different 
HIP1 isoforms seen by western blot analysis. Finally, in chapter 4, we examine the 
putative promoter of the human HIP1A transcript for its general activity and possible 






Figure 1.1: Diagram of the HIP1 protein. The human HIP1 protein consists of 1037 
amino acids while the mouse HIP1 protein comprises 1031 amino acids. The HIP1 
protein has a number of functional domains that suggest a role in endocytosis. At the N-
terminus of HIP1 is an AP180 N-terminal homology domain, which preferentially binds 
to 3-phosphoinositides.  HIP1 also has clathrin and AP2 binding motifs. The central 
portion of the protein is comprised of a coiled coil domain with a leucine zipper. This 
allows HIP1 to form homodimers and heterodimers with HIP1-Related (HIP1-R). The C-






Figure 1.2: Comparison of the 5’ end of the HIP1 gene in human and mouse. The 
HIP1 gene in both mice and humans consists of a relatively large intron 1. Intron 1 of the 
human HIP1 gene is over 139 kilobases while intron 1 of the mouse Hip1 gene is 89 
kilobases. Multiple expressed sequence tags (EST) have been generated that contain 
starting exons located within intron 1 in both species. However, no alternative promoters 







Figure 1.3: Diagram of the 3’end of the HIP1 gene. The HIP1 gene has a total of 31 
exons. The last exon, exon 31, is over 6 kilobases in size but only 53 of these bases are 






USE OF A CRYPTIC SPLICE SITE FOR THE EXPRESSION OF HUNTINGTIN 
INTERACTING PROTEIN 1 IN SELECT NORMAL AND NEOPLASTIC 
TISSUES 
Summary 
Huntingtin Interacting Protein 1 (HIP1) is a 116 kDa endocytic protein that is 
necessary for the maintenance of several adult tissues in vivo.  Its complete deficiency, 
due to homozygosity of a null Hip1 allele, leads to degenerative adult phenotypes.  HIP1 
deficiency also inhibits prostate tumor progression in the prostate cancer prone TRAMP 
mouse model.  To better understand how deficiency of HIP1 leads to such phenotypes, 
we carefully analyzed tumorigenic potential in mice homozygous for a Hip1 mutant 
allele, designated Hip1
Δ3-5
, which is predicted to result in a frame-shifted, nonsense 
mutation in the N-terminal region of the coding sequence.  In contrast to our previous 
studies using the Hip1 “null” allele, an inhibition of prostate tumorigenesis was not 
observed as a result of the homozygosity of the “nonsense” Δ3-5 allele.  Also, it did not 
inhibit breast tumorigenesis in the MMTV-Myc breast cancer-prone background.  To 
more closely examine the contrasting results from the two different Hip1 mutant mice, 
we cultured tumor cells from homozygous Δ3-5 allele bearing TRAMP and MMTV-myc 
mice and discovered the presence of an approximately 110 kDa form of HIP1 in tumor 
cells.  Upon genomic DNA and cDNA sequencing of Hip1 from these tumors, we 
determined that this 110 kDa form of HIP1 is the product of splicing of a cryptic U12-
type AT-AC intron.  This event results in the insertion of an AG dinucleotide between 
exons 2 and 6 and restoration of the original reading frame.  Remarkably, this mutant 
protein retains its capacity to bind lipids, clathrin, AP2, and EGFR providing a possible 
explanation for why tumorigenesis was not altered following this “knockout” mutation.  




investigating the contribution of HIP1 to the homeostasis of specific normal and 
neoplastic tissues at different developmental stages. 
Introduction 
Huntingtin Interacting Protein 1 (HIP1) was first identified by its ability to 
interact with huntingtin, the protein encoded by the gene that is mutated in Huntington’s 
disease [1, 2].  HIP1 and its only known mammalian relative, HIP1-related (HIP1r), were 
subsequently shown to specifically interact with clathrin, AP2 [4, 18-22, 35, 36], and 
epidermal growth factor receptor (EGFR) [5].  Thus, the HIP1 family is widely thought to 
be involved in the regulation of growth factor receptor endocytosis and signaling.  
Additionally, HIP1 and HIP1r contain AP180 N-terminal homology (ANTH) inositol 
lipid-binding domains, which are specific to endocytic proteins [14, 15].  Finally, 
deficiency of HIP1 leads to spinal defects, testicular degeneration, cataracts, adult weight 
loss, and early death [26, 37].  Heterologous expression of full-length HIP1 cDNA 
rescues most of these phenotypes confirming that the phenotypes are due to a loss of 
Hip1 [28]. These in vivo phenotypes indicate that HIP1 is necessary for fundamental 
cellular and organismal homeostasis.  Despite their clear necessity in the maintenance of 
adult cells and tissues, the precise cellular and biochemical function(s) of this protein 
family are yet to be determined.  In fact, several attempts at understanding the effects of 
HIP1/HIP1r deficiency on receptor endocytosis either in cultured cells or in vivo have not 
been successful [26-28]. 
In addition to its function in normal tissue maintenance, HIP1 has been widely 
implicated in tumorigenesis.  HIP1 was discovered to be an amino-terminal partner of 
PDGFβR, in the leukemogenic fusion resulting from a t(5;7) chromosomal translocation 
[10].  HIP1 protein also has been found to be up regulated in multiple human tumor types 
including prostate, colon [9], breast [38], brain [5], and lymphoid [7] cancers.  
Additionally, HIP1 over-expression is prognostic in prostate cancer [9].  Furthermore, 
heterologous human HIP1 over-expression can transform mouse fibroblasts [38], an 
effect that we propose to be due to altered growth factor receptor endocytosis and 
subsequent signal transduction cascades.  
To examine the role of HIP1 in prostate cancer, we have previously used mutant 
mice that are deficient in HIP1 due to a spontaneous targeting event (Hip1
null




these HIP1-deficient mice were crossed with the transgenic adenocarcinoma of mouse 
prostate (TRAMP) mice [39], the HIP1-deficient progeny mice contained fewer and less 
aggressive prostate tumors than their littermate TRAMP control mice [6].  We have 
expanded these studies by using a different tumor model system (MMTV-MYC model of 
breast cancer) and a “third generation” Hip1 knockout mouse allele (the Hip1
3-5
) that 
does not provide the confounding issues associated with the above-described spontaneous 
“null” allele [26], such as possible altered expression of HIP1-neighboring genes caused 
by the neomycin cassette.  In the present study, we report the surprising result that 
Hip1
Δ3-5/ Δ3-5 
are equally, if not more, prone to the development of prostate and breast 
tumors than Hip1 wild type mice.  Furthermore, we found that the tumor cells from the 
Hip1
Δ3-5/ Δ3-5 
genetic background express a truncated form of the HIP1 protein that is the 
result of a novel cryptic splicing event.  These results have important implications not 
only for the role of HIP1 and its interacting proteins in normal and neoplastic cell biology 
but also for the development and analysis of mouse model systems with specific targeting 
events. Our data emphasize the value of how sequencing the transcript that is actually 
produced by an engineered knock-out allele can reveal novel types of molecular 
compensation at the level of splicing. 
Materials and Methods 
Mice   







 [26],  TRAMP ([39], C57BL/6, The Jackson Laboratories) and 
MMTV-myc ([40], MammJ/FVB, Gift from Lewis Chodosh) allele-containing mice were 
maintained and bred under SPF conditions as per UCUCA guidelines at the University of 
Michigan.  The TRAMP and MMTV-myc allele-containing mice were maintained on 
pure genetic backgrounds.  Since the other alleles were maintained on a mixed 
C57BL/6;129svj background, all experiments were performed using the appropriate 
littermate controls.   
Tumor analysis in MMTV-myc mice   









with calipers.  The mice were sacrificed at one year of age or if a tumor impeded 
movement or ulcerated. 
Tumor cell culture   
Fresh tumor samples from MMTV-myc and TRAMP mice were cut into 1 mm 
sections, added to DMEM containing 2.2 mg/ml collagenase (Sigma), and incubated for 1 
hour at 37
o
C with agitation every 10 minutes.  The digested samples were filtered 
through a 100 m nylon cell strainer (Falcon) then centrifuged at 1,000 rpm for 10 
minutes.  The supernatant was removed, and the remaining cells were suspended in 
DMEM/10% FBS and plated onto 10 mm dishes.  Cells were passaged every 3 days into 
fresh media. 





 mice were maintained on a mixed 
C57BL/6;129svJ background, and the TRAMP mice were
 
maintained on a pure C57BL/6 




 mice were 







, and 15 TRAMP/Hip1
null/null 
littermates were 
analyzed for tumors at 6.5 months.  Prior to these necropsies, a group of mice from these 
cohorts either unexpectedly died or became moribund and required euthanasia.  This 
survival data for each of these observation groups was compared.
 
 
Genomic DNA sequencing   
High-fidelity PCR amplification of the 3 kb genomic region between exons 2 and 
6 of Hip1 from a MMTV-myc;Hip1
3-5/ 3-5
 tumor was performed.  The resulting products 
were cloned, and single-run complete sequencing was performed on two independent 
clones. 
Sequence analysis 
The alignment of sequences from wild type Hip1 cDNA or MMTV-myc;Hip1
3-
5/ 3-5
 tumor genomic DNA was analyzed using a combination of Sequencer version 4.5 





Total RNA was isolated from cultured tumor cells, tissues, and early passage 
mouse embryonic fibroblast (MEF) extracts using the TRIzol reagent (Invitrogen). 
Reverse-transcriptase PCR (RT-PCR) 
RT-PCR was performed on total RNA using the SuperScriptTM One-Step RT-
PCR system (Invitrogen) and primers specific to Hip1 exon 1 (5’-
ATGAAGCAGGTATCCAACCCGCTGCCC-3’, forward primer) and the exon 14/15 
junction (5’-ATTAGCCTGGGCCTTTCTTTCTATCTC-3’, reverse primer) of murine 
Hip1 cDNA.  Resulting products were separated on 0.8% agarose gels.  Products were 
extracted from the gel and amplified by nested PCR using primers specific to the exon 
1/2 junction (5’-TTCGAGCGGACTCAGACGGTCAGCGTC-3’-forward primer) and 
the exon 13/14 junction (5’-ATGGCCCGCTGGCTCTCAATCTTCATG-3’ reverse 
primer) of murine Hip1 cDNA.  Products were again run on 0.8% agarose gels, extracted, 
and directly sequenced using the PCR primers that were used for the amplification.  PCR 
products that did not yield readable sequence were cloned using the TOPO TA Cloning 
Kit for Sequencing (Invitrogen).  Multiple clones were selected, and plasmid DNA was 
isolated and sequenced. 
Northern blot analysis of mouse embryonic fibroblast (MEF) mRNA 
Poly (A) RNA was isolated from total RNA using the Poly(A) Purist MAG 
protocol (Ambion).  Then, 5ug of this poly(A) RNA was separated on a 1% agarose gel 
with 6% formaldehyde, stained with ethidium bromide, transferred to Nytran membrane 
(Schleicher & Schuell), and cross-linked.  The membrane was prehybridized in a buffer 
containing 5X SSC, 5X Denhardt solution, 1% sodium dodecyl sulfate (SDS) (wt/vol), 
and 100 g of denatured salmon sperm DNA/ml for 3 h at 65 C.  For the mouse Hip1 
Northern probe, an 850-bp EcoR1 and Not1 digested fragment encoded by mHip1 exons 
10-14 was used.  The probe was 
32
P labeled using a random-primed labeling kit 
according to manufacturer’s directions (Roche).  The blot was hybridized overnight at 
65 C, washed twice in 2X SSC for 20 min, once in 1X SSC for 10 min, and twice in 0.1X 
SSC for 10 min.  The blot was exposed for 4 to 5 days on Kodak Biomax film.  The 





Tissue preparation and western blot analysis 
Tissue harvesting, preparation, and immunoblotting of tissues was performed as 
previously described [27].  A polyclonal anti-HIP1 (1:5,000, UM354) antibody was used 
to detect HIP1 expression in MMTV-myc, TRAMP and Mx1-Cre mice, and polyclonal
 
anti-actin (1:1000, Sigma) antibody was used as a control.  
polyIpolyC (pIpC)-treatment of Mx1-cre mice 
Mice were injected intraperitoneally with 250 ug/mouse of polyinosinic-
polycytidylic acid (pIpC, Sigma, St. Louis, MO) every other day for 7 or 14 days as 
previously described [41, 42].   
Bone marrow culture 
Mouse bone marrow cell monocytic culture was carried out as previously 
described (Bradley, 2007), except that RPMI-1640 media and M-CSF (1 ng/ml, Sigma, 
St. Louis, MO)
 
was used and femur bone marrow was plated onto 100 mm dishes.
 
 One 
week later, cells were directly lysed in the dishes and collected for protein analysis. 
 
Co-immunoprecipitation of HIP1 and EGFR and endocytic factors 
Full-length and mutant EGFR and HIP1 cDNA constructs in pcDNA3 have 
previously been described [5].  A 15-cm dish of 70% confluent 293T cells was 
transfected with 20 μg of HIP1 cDNA and 20 μg of EGFR cDNA using Superfect reagent 
(Qiagen).  Twenty-four hours post-transfection, the cells were lysed using an all-purpose 
lysis buffer [50 mmol/L Tris (pH7.4), 150 mmol/L NaCl, 1% Triton X-100, 1.5 mmol/L 
MgCl2, 5 mmol/LEGTA, 10% glycerol, Complete EDTA-free protease inhibitor tablets 
(Roche), 30 mmol/L sodium pyrophosphate, 50 mmol/L sodium fluoride, and 100μmol/L 
sodium orthovanadate].  Five milligrams of protein were incubated with pre-immune 
serum, polyclonal anti-HIP1 serum (UM323), or sheep polyclonal anti-EGFR (Upstate).  
One hundred microliters of a 3:1 slurry of protein G-sepharose beads (GE Healthcare) in 
lysis buffer were then incubated with the lysate-antibody mixture at 4ºC for 60 min with 
rotation.  The protein G pellets were washed four times with 1 mL of lysis buffer.  The 
entire pellet was dissolved in SDS sample buffer, boiled for 5 min, separated on 7% SDS-
PAGE, and transferred to nitrocellulose membranes.  Antibodies used for western blot 




immunoglobulin G1, 400 ng/mL), anti-adaptin-α antibody (rabbit polyclonal, BD 
Biosciences), anti-clathrin heavy chain TD-1 antibody (kind gift of Linton Traub, 
University of Pittsburgh), and an anti-EGFR antibody (sheep polyclonal antibody, 
Upstate Biotechnology, Charlottesville, VA). 
Generation of HIP1 expression constructs 
Generation of the pcDNA3/FL HIP1 expression construct was reported previously 
[9].  PCR mutagenesis using pcDNA3-FL HIP1 as a template was used to generate the 
insert for the pcDNA3/hHIP1Δ3-5/insAG expression construct.  Two initial PCR 
products were generated using two separate pairs of primers.  The first primer pair 
consisted of a forward primer specific to exon 1 (5’-AGGGAGACCCAAGCTTGGTA-
3’including a KpnI restriction site) and an engineered reverse primer (5’-
GGGATTCTTTCTGGCGTGTTTTTCCTT-3’) consisting of sequence from exon 2, an 
AG dinucleotide, and sequence from the 5’ portion of exon 6.  The second primer pair 
consisted of an engineered forward primer (5’-
AACACGCCAGAAAGAATCCCAGGTTCC-3’) consisting of sequence from the 3’ 
portion of exon 2, an AG dinucleotide, and sequence from exon 6 and a reverse primer 
specific to exon 14 (5’-TTCTATCTCAGACAGGCTCC-3’; just 3’ of the EcoRI 
restriction site at position 1290 of the coding sequence).  The resulting PCR products 
were used as templates in a second PCR reaction to generate the hHIP1Δ3-5/insAG 
insert.  The hHIP1Δ3-5/insAG insert was cloned into pcDNA3-FL HIP1 using the KpnI 
and EcoRI restriction sites.  
Generation and purification of GST-fusion proteins 
The 5’ portions of pcDNA3/FL HIP1 and pcDNA3/hHIP1Δ3-5/insAG were 
cloned into pGEX4T.1 to generate GST-HIP1wt (amino acids 1-430) and GST-HIP1Δ3-5 
(amino acids 1-337) expression constructs, respectively.  The HIP1wt and HIP1Δ3-5 
inserts cloned into the pGEX4T.1 vector were generated by PCR amplification using the 
forward primer, 5’-CCGGAATTCATGGATCGGATGGCCAGC-3’, and the reverse 
primer, 5’-CCGCTCGAGACAGTCGTCGGCCGCCTGC-3’ and pcDNA3/FL HIP1 and 
pcDNA3/hHIP1Δ3-5/insAG as templates.  Constructs were verified by sequencing.  The 
GST-HIP1wt and GST-HIP1Δ3-5 fusion proteins were expressed in E. coli strain BL21 






C.  Bacteria were pelleted and resuspended in PBS containing protease inhibitors 
(Roche Diagnostics).  Resuspended cells were lysed by sonication, and Triton X-100 was 
added to a final concentration of 2%.  The mixture was centrifuged at 12,000 x g for 10 
min.  Following centrifugation, the supernatant was added to glutathione sepharose 4 
beads (50% slurry) and incubated at room temperature for 30 min.  The beads were 
washed 3 times with PBS and elution buffer (50mM Tris-HCL, 10mM reduced 
glutathione [pH 8.0]) to elute the fusion proteins.  Eluted proteins were dialyzed in PBS 
at 4
o
C for 2 h and again overnight.  Dialyzed proteins were concentrated using Aquacide 
(Calbiochem), and protein concentrations were determined by SDS-PAGE and 
Coomassie blue staining.  Proteins were further analyzed by western blot analysis using 
an anti-GST antibody (Cell Signaling Technologies) and an anti-HIP1 antibody 
(UM354). 
Lipid-binding assay 
Lipid-binding assays using PIP strips and PIP arrays (Echelon) were performed 
according to manufacturer’s protocol.  Briefly, either PIP strips or PIP arrays were 
incubated overnight at 4
o
C with 12.5 µg of purified protein in TBST with 1% milk.  
Binding was detected using anti-GST antibody (1:5000) or UM354 (1:2000) in TBST 
with 1% milk.  Anti-rabbit secondary antibodies conjugated to horse radish peroxidase 
(HRP) were used at 1:5000 (for anti-GST) or 1:2000 (for UM354) in TBST with 1% 
milk. 





 mice were maintained on a mixed 
C57BL/6;129svJ background, and the TRAMP mice were maintained on a pure C57BL/6 




 mice were 
performed as previously described [6]. Fourteen TRAMP; Hip1
Δ3-5/Δ3-5





 and 15 TRAMP;Hip1
null/null
 littermates were analyzed 
for tumors at 6.5 months. Prior to thes necropsies, a group of mice from these cohorts 
either unexpectedly died or became moribund and required euthanasia. This survival data 




RNA isolation and northern blot 
Total RNA was isolated from cultured tumor cells, tissues, and early passage 
mouse embryonic fibroblast (MEF) extracts using the TRIzol reagent (Invitrogen). Poly 
(A) RNA was isolated from total RNA using the Poly(A) Purist MAG protocol 
(Ambion). Then, 5µg of this poly(A) RNA was separated on a 1% agarose gel with 6% 
formaldehyde, stained with ethidium bromide, transferred to Nytran membrane 
(Schleicher & Schuell), and cross-linked. The membrane was prehybridized in a buffer 
containing 5X SSC, 5X Denhardt solution, 1% sodium dodecyl sulfate (SDS) (wt/vol), 
and 100µg of denatured salmon sperm DNA/mL for 3 hours at 65
o
C. For the mouse Hip1 
Northern probe, an 850-bp EcoR1 and Not1 digested fragment encoded by mHip1 exons 
10-14 was used. The probe was 
32
P-labeled using a random-primed labeling kit according 
to manufacturer’s directions (Roche). The blot was hybridized overnight at 65
o
C, washed 
twice in 2X SSC for 20 min, once in 1X SSC for 10 min, and twice in 0.1X SSC for 10 
min. The blot was exposed for 4 to 5 days on Kodak Miomax film. The mRNA 
abundance was normalized with the signal for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH). 
Tissue preparation and western blot analysis 
Tissue harvesting, preparation, and immunoblotting of tissues was performed as 
previously described [27]. A polyclonal anti-HIP1 (1:5,000, UM354) antibody was used 
to detect HIP1 expression in MMTV-myc, TRAMP and Mx1-Cre mice, and polyclonal 
anti-actin (1:1,000, Sigma) antibody was used as a control. 
Co-immunoprecipitation of HIP1 and EGFR and endocytic factors 
Full-length and mutant EGFR and HIP1 cDNA constructs in pcDNA3 have 
previously been described [5]. A 15-cm dish of 70% confluent 293T cells was transfected 
with 20µg of EGFR cDNA using Superfect reagent (Qiagen). Twenty-four hours post-
transfection, the cells were lysed using an all-purpose lysis buffer [50 mmol/L Tris 
(pH7.4), 150 mmol/L NaCl, 1% Triton X-100, 1.5 mmol/L MgCl2, 5 mmol/L EGTA, 
10% glycerol, Complete EDTA-free protease inhibitor tablets (Roche), 30 mmol/L 
sodium pyrophosphate, 50 mmol/L sodium fluoride, and 100µmol/L sodium 
orthovanadate]. Five milligrams of protein were incubated with pre-immune serum, 




hundred microliters of a 3:1 slurry of protein G-sepharose beads (GE Healthcare) in lysis 
buffer were then incubated with the lysate-antibody mixture at 4
o
C for 60 min with 
rotation. The protein G pellets were washed four times with 1 mL of lysis buffer. The 
entire pellet was dissolved in SDS sample buffer, boiled for 5 min, separated on 7% SDS-
PAGE gel, and transferred to nitrocellulose membranes. Antibodies used for western blot 
analysis were the anti-HIP1/4B10 antibody (mouse monoclonal, human anti-HIP1 
immunoglobulin G1, 400 ng/mL), anti-adaptin-α antibody (rabbit polyclonal, BD 
Biosciences), anti-clathrin heavy chain TD-1 antibody (kind gift of Linton Traub, 
University of Pittsburgh), and an anti-EGFR antibody (sheep polyclonal antibody, 
Upstate Biotechnology, Charlottesville, VA). 
Results 
Germ line deletion of Hip1 exons 3 thru 5 leads to a phenotype similar to that of 
Hip1null mice 
The Hip1 gene has a complex structure consisting of 32 exons spread over 220 
kilobases.  To examine the role Hip1 plays in development and disease, we have 
generated a series of Hip1 [26] and Hip1r [27] mutant alleles.  The original Hip1
null 
allele 
was serendipitously generated in an attempt to knock the human HIP1/PDGFβR fusion 
cDNA into the mouse Hip1 genomic locus [26].  Using this null allele, we previously 
reported that HIP1 deficiency leads to a complex degenerative mouse phenotype [26] and 
impaired tumor progression in transgenic adenocarcinoma of the mouse prostate 
(TRAMP) mice [6].  Because of the complex structure of this original allele and the 
resultant multi-tissue phenotype, we generated a conditional Hip1 mutant allele 
(Hip1
loxp
).  To do this, we generated a targeting vector to introduce loxP sites flanking 
Hip1 exons three through five, which encode a significant portion (80%) of the ANTH 
domain.  As predicted, cre-mediated recombination of these loxP sites resulted in the 
deletion of exons 3-5 as well as the neomycin selection cassette [26].  The resulting allele 
(Hip1
Δ3-5
) contains not only a deletion of most of the ANTH domain sequences but also a 
frame-shifted, nonsense mutation that fuses exon 2 to exon 6.  Protein expressed from 
this mutant allele is predicted to be a truncated amino terminal 10 kDa protein lacking the 
ANTH, clathrin-binding, AP2-binding, coiled-coil, and Talin homology domains 




Previously, mice homozygous for the Δ3-5 allele were found to exhibit 
degenerative phenotypes similar to the Hip1
null/null
 mice (e.g., kypholordosis and testicular 
degeneration/infertility).  However, there were two differences in the phenotypes 
associated with these mice.  First, the Hip1
3-5/ 3-5
 mice did not have cataracts.  Second, 
the Hip1
3-5/ 3-5
 mice did not display perinatal lethality [26].  These differences suggested 
that either the Hip1
3-5
 allele is not a complete null allele or that the serendipitous Hip1
null
 
allele affects neighboring genes and that those effected genes (rather than Hip1) are 
necessary for embryogenesis and lens homeostasis.   
Breast and prostate tumorigenesis is not inhibited in Hip1
Δ3-5/Δ3-5 
mice 
Since HIP1 is known to transform mouse fibroblasts [38] and is over-expressed in 
multiple human cancers [9], it has been hypothesized to play a role in tumorigenesis.  We 
have previously demonstrated that HIP1 deficiency inhibits prostate tumor progression in 
TRAMP mice [6].  To examine further the involvement of HIP1 in tumor development, 
we analyzed the effect of HIP1 deficiency on breast tumorigenesis using the MMTV-myc 
mammary tumor model [40].  Because of its less complex structure but similar phenotype 
to the Hip1
null
 allele, we have used the Hip1
Δ3-5 
allele in our subsequent studies of the role 
of HIP1 in tumorigenesis.  MMTV-myc and TRAMP transgenic mice were generated in 
both the Hip1 “null” and 3-5 genetic backgrounds.  The MMTV-myc mice were 
sacrificed prior to or at 12 months of age and analyzed for the appearance and 
progression of breast tumors (Figure 2.2).  Consistent with our previous results using the 
TRAMP mice, the HIP1 “null” background inhibited tumorigenesis induced by the 
MMTV-myc transgene [6] such that none of the 6 Hip
null/null
;MMTV-myc mice (0%) 
analyzed developed breast tumors.  In contrast, 3 of 16 Hip
+/null
;MMTV-myc mice (18.8 
%) analyzed developed breast tumors.  This trend supports the hypothesis that HIP1 
deficiency inhibits breast tumorigenesis (Figure 2.3A). 
The use of the Δ3-5 allele (compared to the null allele) to generate a HIP1 
deficient background resulted in a different effect on tumorigenesis.  For the MMTV-myc 
mice, 8 of 18 (44%) Hip1
Δ3-5/Δ3-5 
mice and 19 of 37 (51%) Hip1
+/Δ3-5 
mice developed 
palpable breast tumors (Figure 2.3A).  This level is significantly higher than the 19% 
breast tumor incidence in MMTV-myc mice with the Hip1
+/null
 backgrounds and the 0% 
incidence in the Hip1
null/null




breast tumor metastasis in mice that contained the Δ3-5 allele (Figure 2.3B).  Both 
multiple synchronous primary breast tumors (Figure 2.3C) as well as multiple metastatic 







 mice produced similar results with a smaller cohort of mice 
available for tumor analysis (Figure 2.4).  We initially planned to compare larger groups 
of 6-month-old heterozygous and homozygous TRAMP;Hip1
Δ3-5 
mice.  This plan was 





 mice developed prostate cancer at a similar frequency and to a 
similar extent in the TRAMP background and survived to at least 6 months of age.  As 
expected, when we performed this fourth TRAMP experiment we observed that 84 % 
(15/18) and 93% (14/15) of the TRAMP mice that were heterozygous and homozygous 
for the null allele, respectively, survived to 6 months of age (Figure 2.5A).  
Unexpectedly, Hip1
Δ3-5
;TRAMP mice (both heterozygotes and homozygotes) began to 
die spontaneously by 4 months of age and only 35% (5/14) of the homozygotes and 69% 
(9/13) of the heterozygotes survived to the 6 month point (Figure 2.5A).  This reduction 
in survival associated with the Hip1
Δ3-5 
allele was not due to the effects of the Hip1
Δ3-5/Δ3-5 
degenerative phenotype (e.g., kypholordosis, dwarfism, etc.) as it was observed in both 
the heterozygotes and the homozygotes.  In the TRAMP mice that were available for 
tumor analysis we found that 4 of the 5 surviving homozygous Hip1
3-5
 allele bearing 
TRAMP mice had gross prostate tumors (80%) and 3 of those 4 tumor bearing mice 
displayed gross evidence for multiple synchronous primary tumors in different lobes of 
the prostate (Figure 2.5B).  In comparison, there was no evidence for multiple primary 
tumors in the Hip1
3-5/+
 (7 of these 9 (75%) mice had prostate cancer), Hip1
null/+
 (6 of the 
18 (33 %) mice had prostate cancer) or Hip1
null/null
 (5 of the 15 (33%) had prostate 
cancer) TRAMP mice. 
A novel cryptic splicing event allows for expression of a large mutant HIP1 protein 
The difference in tumor incidence in the Hip1
null/null
 mice and the Hip1
3-5/ 3-5
 
mice suggests either that (1) the original null allele alters the expression of neighboring 
genes and that it is those genes that influence tumorigenesis or (2) the Δ3-5 allele is not a 
completely null allele.  To investigate these two possibilities, we examined normal and 




expression of polypeptides that react with HIP1-specific antibodies.  Extracts from these 
tissues were analyzed by western blotting for the presence of either full-length or 
truncated HIP1 protein using a polyclonal rabbit antibody (UM354) specific for the 
amino-terminal end of the HIP1 protein (Figure 2.6A, lanes 5-10).  Additionally, tumor 
tissue was dissociated and cultured so that tumor cells from these mice could be 
analyzed.  Results of this analysis indicated that a truncated protein approximately 10 
kDa smaller than the wild type HIP1 protein was expressed in the Hip1
3-5/ 3-5
 tumor-
derived cultured cells (Figure 2.6A, lanes 1 and 2 versus lanes 3 and 4).  Extracts derived 
from the bulk of the tumor as well as other select tissues from these mice showed the 
expected lack of expression (Figure 2.6A, lanes 5-10). 
In the construction of the 3-5 allele, exons 3 through 5 were deleted not only to 
disrupt the ANTH domain but also to ensure that the splicing of exon 2 with exon 6 or 
any of the other exons downstream of exon 6 would result in a frame shift that would 
lead to premature truncation at the amino terminal end of the protein.  Therefore, the 
presence of a truncated HIP1 protein in these tumor cells that is only 10 kDa smaller than 
the wild type protein was quite surprising (Figure 2.6A, lanes 3 and 4).  To identify the 
mRNA that encodes for this truncated HIP1 protein, we performed reverse transcriptase 
polymerase chain reaction (RT-PCR) using total RNA derived from TRAMP and 
MMTV-myc tumor-derived cultured cells.  Primers specific to the exon 1 and the exon 
14/15 junctions of the HIP1 cDNA sequence (NCBL BLAST-Accession # NT_039314) 
were used in the initial RT-PCR reaction.  We detected a PCR product of the expected 
size (1.6 kb) in tumor-derived cells generated from wild type mice and from mice 
heterozygous for the 3-5 allele (Figure 2.6B, lanes 2, 4, 6-8 wt arrow).  An additional 
band approximately 300 bp smaller (i.e., 1.3 kb) than expected was observed in both 
heterozygous and homozygous mice.  These bands were excised from the gel, PCR 
amplified using nested primers, and the products were sequenced.  The cDNA sequence 
for the nested 1.6 kb product was identical to that of the wild type Hip1 cDNA.  
Interestingly, the sequence of the nested 1.3 kb product contained exon 2 fused to exon 6 
with a dinucleotide AG insertion in the junction.  This dinucleotide insertion put the exon 
2/6 fusion in frame (Figure 2.7) such that it encodes for an only slightly truncated HIP1 




To examine further the above-described HIP1 mutant protein, we sequenced the 
Hip1 gene from genomic DNA derived from cultured tumor cells.  Surprisingly, we did 
not detect a mutation.  However, careful analysis of the genomic sequence revealed two 
unique findings to explain the aberrant protein and transcript expression.  First, we found 
that intron 2 uses a rare “AT-AC” U12 dependent splicing mechanism (Figure 2.6C).  
This type of intron, which represents approximately 1% of the introns in the mammalian 
genome [43], consists of 5’AT and 3’AC splice sites.  Second, we found that the intron 5 
splice acceptor (a typical AG) is immediately preceded by an AC.  This ACAG sequence 
allows for the incorporation of an AG dinucleotide into the coding sequence of the 
mRNA transcript and serendipitous maintenance of the original reading frame.  The 
predicted size of this mutant protein is 106 kDa (Figure 2.1 schematic), which is very 
similar to the size of the observed protein product (Figure 2.3A, lanes 3 and 4). 
Mutant HIP1 3-5insAG protein expression in embryonic and adult lung and brain 
tissues 
The presence of this AG dinucleotide insertion that placed exons 2 and 6 in frame 
in both 3-5 heterozygous and 3-5 homozygous cells led us to re-evaluate whether or 
not Hip1 protein is expressed in normal tissues.  We isolated select normal cells and 
tissues from wild type, 3-5 heterozygous, and 3-5 homozygous mice and analyzed 
them for the presence of the HIP1 3-5insAG protein product.  Using northern blot 
analysis of embryonic fibroblast RNA (Figure 2.8A), we found that the truncated 
message was evident in homozygous mice (lane 2) when analyzed beside wild type RNA 
(lane 1).  Using RT-PCR, we also found that tissue from the brains, lungs, and kidneys of 
3-5 heterozygous and homozygous mice contained the Hip1 3-5insAG mRNA (Figure 
2.8B).  No PCR product representing the Hip1 3-5 mRNA was observed in wild type 
mice (Figure 2.8B, lanes 3, 6 and 9).  We also found that extracts from cultured, early 
passage embryonic fibroblasts and embryonic brain contained easily detectable truncated 
HIP1 3-5insAG protein product (Figure 2.9).  In contrast, nearly all adult tissues, with 
the exceptions of the lung and brain (Figure 2.8C, lanes 6 and 8), displayed very low 
levels of HIP1 polypeptide expression (Figure 2.8C, lanes 2, 4 and 10; use of an amino-
terminal polyclonal antibody UM354).  Either the diminished expression or the lack of 




degenerative phenotype similar to that of the original homozygous “null” mice.  In 
addition to the altered expression levels of the HIP1 peptides in various tissues, we noted 
that the migration of the HIP1 protein in the embryonic brain was quite different from 
that in the adult brain.  Analysis of the Hip1 protein product in embryonic, newborn, pre-
weaned, and adult mice indicated that this differential expression correlates with 
developmental stage, with the product in the adult brain migrating distinctly slower or co-
migrating with the wild type form of HIP1 (Figure 2.8D, lanes 2, 4 and 6).  The 
molecular explanation of this striking developmental correlation remains to be 
determined. 
Next, using the original Hip1
loxp/loxp
 mice [26], we generated a tissue-specific 3-
5 recombinant allele.  By crossing the Hip1
loxp
 mice with mice carrying an interferon 
inducible Mx1-Cre transgene, we generated mice that expressed the 3-5 allele only in 
cells of the adult hematopoietic system, liver, and kidney following pIpC-mediated 
induction of Cre expression [42, 44].  With these mice, we examined whether the gross 
phenotype of the germ line 3-5 mouse could be recapitulated only in the isolated adult 
tissues.  Interestingly, western blot analysis of extracts from the spleen, liver, kidney 
(Figure 2.10A), and bone marrow (Figure 2.10B) of Mx1-Cre induced mice demonstrated 
that the expression of the truncated HIP1 protein was most prominent in the spleen 
(Figure 2.10A, lanes 9-11) and bone marrow (Figure 2.10B lanes 3, 5, 7, 8) and loss of 
HIP1 expression altogether was frequently observed in the normal liver (lane 4-6, panel 
1) and kidney (Figure 2.10A, lanes 9-11, panel 4) but as expected not in brain, heart, eye 
(Figure 2.10A), uterus, ovary or the GI tract (data not shown).  It is of interest that in the 
two tissues, liver and kidney, where we observed HIP1 protein deficiency due to a 
complete recombination event did not display the degenerative phenotype observed in the 
germ line recombined 3-5 mice.  We therefore conclude that tissue specific HIP1 
deficiency in the liver and kidney does not induce the knockout phenotype.  
Unfortunately, we could not make this conclusion in the hematopoietic system as despite 
repeated attempts to induce interferon with pIpC, the complete recombination of the 
Hip1
loxp
 allele in the Mx1-cre mice was not achieved in hematopoietic tissues (Figure 
2.10B, lane 7) and, therefore, a significant amount of wild type Hip1 expression remained 




These findings also suggest the possibility that the truncated HIP1 protein may be 
preferentially expressed in dividing cells, including tumorigenic cells.  This prediction is 
supported by the finding that 3-5insAG protein was present in the fibroblasts and brains 
of 3-5 mouse embryos at E17.0 day (Figure 2.8C, lanes 5, 6, 11, 12).  Furthermore, we 
discovered a gross liver tumor in an Mx1Cre;Hip1
loxp/+
 mouse (Figure 2.10C).  The tumor 
from this mouse expressed a truncated 3-5 protein product while the surrounding 
“normal” liver did not.  Additionally, we identified a trend in which the spleen sizes of 
the Hip1 floxed, Mx1cre, pIpC-treated mice increased, although frank hematopoietic 
malignancies were not observed (data not shown). 
The HIP1 3-5insAG protein retains its ability to bind lipids, clathrin, AP2, and 
EGFR 
We have observed some slight phenotypic differences between the Hip1
3-5 3-5 
mice and the Hip1
null/null
 mice [26].  These differences included absence of cataracts or 
perinatal death in the Hip1
3-5 3-5 
mice, increased mortality from tumors in the 
TRAMP;Hip1
3-5
 mice relative to the TRAMP;Hip1
null/null
 mice (Figure 2.5A), no 
decrease in breast or prostate tumorigenesis in Hip1
3-5
 allele bearing backgrounds 
(although there was a trend toward more tumors; Figure 2.3A), and a liver tumor in a 
young, conditional Hip1
3-5
 heterozygous mouse (Figure 2.10C).  Given these 
differences, we examined whether the Hip1 3-5insAG protein product possesses all or a 
subset of its cellular activities that promote normal and neoplastic cell 
proliferation/survival by assessing its ability to bind to lipids, endocytic factors, and 
EGFR.   
Because this truncated protein retains its clathrin-, AP2-, and EGFR-binding 
regions, we predicted that the Hip1 3-5insAG protein product would have the ability to 
bind these proteins.  To test this hypothesis, we expressed the HIP1
Δ3-5/insAG
 cDNA in 
293T cells, immunoprecipitated the mutant protein with an anti-HIP1 polyclonal antibody 
(UM323, bleed 8/2002), and immunoblotted the precipitates to determine the presence or 
absence of the endocytic proteins and EGFR. As expected, the truncated mutant protein 
bound EGFR, clathrin and AP2 (the alpha subunit) (Figure 2.11A, lanes 11 and 15).  In 
contrast, expression of a human HIP1 mutant cDNA construct that lacks the AP2- and 




and 16).  Also, it should be noted that the interaction between HIP1 and EGFR was 
apparently enhanced by the deletion of either the sequences encoded for by exons 3-5 
(Figure 2.11A, lanes 11 and 15 compared to 10 and 14) or the domains that bind to 
endocytic proteins (Figure 2.11A, lanes 12 and 16), suggesting that the interaction of 
HIP1 with EGFR is not indirectly mediated by the its binding with clathrin and/or AP2. 
Since 80% of the sequence of the lipid binding ANTH domain is deleted from the 
HIP1 3-5insAG protein (Figure 2.1), we predicted that this mutant would likely not 
retain its lipid binding activity.  Interestingly, most of the key residues that are important 
for the direct binding of the ANTH domain-containing proteins to PI(4,5)P2 were retained 
in the 3-5 protein product (key residues are bold in Figure 2.1) [14, 15].  However, one 
key residue (homologous to K76 of epsin) that has been shown to be important in binding 
to the Ins(1,4,5)P3 head group [15] is deleted in the truncated 3-5 protein.  To determine 
whether the 3-5 protein product retained its lipid-binding capacity, we examined lipid 




 fusion proteins.  We 
generated and glutathione-sepharose purified GST-fusion proteins that contained the first 




 proteins, respectively (Figure 
2.11B).  The purified proteins were separated by SDS-PAGE and Coomassie stained to 
quantitate the amount of recombinant protein.  The purified recombinant proteins were 
also analyzed by western blot to ensure interaction with anti-GST and anti-HIP1 
antibodies (Figure 2.11B).  Next, the purified proteins were incubated with Echelon-
generated PIP strips to examine whether the fusion proteins were capable of binding 
lipids.  Both the wild type and the HIP1
Δ3-5/insAG
 mutant fusion proteins bound PtdIns(3)P 
predominantly (Figure 2.12).  These results were confirmed using PIP arrays (Echelon), 
which were used to further examine the differential abilities of these proteins to bind to 
lipids.  Interestingly, these truncated fusion proteins displayed a higher specific binding 
to PtdIns(3)P than to polyphosphorylated inositol lipids.  On the other hand, our previous 
studies using the full-length HIP1 expressed in 293T cells indicated that its lipid binding 
preference was polyphosphorylated 3-phosphoinositides [16].  Our contradictory results 
may be due to either the absence of the carboxyl-terminal end of the protein, differences 
in proteins expressed in bacteria versus mammalian cells or differences in the materials 




issue.  Nevertheless, the specific inositol lipid binding capacity of the ANTH domain is 
retained in the Hip1 3-5insAG protein.     
Discussion 
We have previously demonstrated that the HIP1 family of proteins are 
biologically important since both single Hip1 [26, 37] and double Hip1/Hip1r [28] 
knockout mice have adult degenerative phenotypes and HIP1 protein expression is 
altered in multiple cancers [9].  However, the exact function of this protein family 
remains unclear, and more detailed cellular and biochemical analyses are needed to 
validate predicted functions and identify novel ones.  In the current study, we describe a 
novel form of HIP1 that is expressed in vivo as the result of a novel cryptic splice event 
between a 5’ AT-AC intron (intron 2) and a 3’ GT-AG intron (intron 5).  These results 
are important for both technical and functional reasons.  First, it illustrates an unpredicted 
cryptic splicing event in a previously predicted “loss of function” gene targeting event, 
and, second, this type of cellular natural selection may provide clues to the function of 
HIP1 in normal and neoplastic cells.   
The technical aspects of these findings have provided us a very important lesson.  
The targeting event that we initially designed led to a mutation in the AT-AC intron 2.  
The rare splicing event that we observed reflects preferential splicing between splice sites 
of the same class.  The identification of rare U12-dependent intron splicing sites or AT-
AC introns will be important for all proteins with similar genetic structures [43].  This 
finding has also raised an intriguing possibility that such splicing events might occur in 
normal cells leading to the expression of unexpected polypeptides.  Interestingly, the rare 
AT-AC intron 2 is conserved in both the human and mouse Hip1 genes.  This observation 
is consistent with previous reports that U12-type introns are usually conserved 
phylogenetically [45].  It has been reported previously, that genes with nonredundant, 
crucial cellular activities may have strong selective evolutionary pressure against the 
conversion of U12- to U2-type introns and, therefore, have retained them.  HIP1 supports 
this assertion as HIP1 clearly has nonredundant, crucial activities as evidenced by the fact 




In terms of HIP1 function, it is evident that the expression of the truncated mutant 
protein in adult lung and brain tissue does not prevent the adult degenerative phenotypes, 
such as kypholordosis or testicular degeneration.  The discovery here of concomitant 
expression of HIP1 sequences in the Hip1 3-5 homozygous mice and the degenerative 
phenotype suggests that this mutant protein may not be completely functional in normal 
cells.  In contrast, the presence of the truncated mutant protein in tumor cells may explain 
why tumorigenesis is not inhibited by the homozygosity of this allele.  This proposal is 
supported by the finding that this mutant protein retains some of its functions (i.e., the 
ability to bind to lipids, clathrin, AP2, and EGFR).  These findings illustrate a 
prototypical example that provides insights into how mouse modeling may lead to 
insertion mutations and unpredicted, active protein products. 
The maintenance of AP2-, CHC-, EGFR- and lipid-binding functions in the 
truncated mutant HIP1 protein suggests that another HIP1 cellular function must 
contribute to the gross phenotype of the mutant mice.  This unknown function likely 
explains why we were unable to identify endocytic defects in either of the mutant mouse 
systems.  Future studies are required to understand the molecular modifications and 
sequences of the various forms of HIP1 that are expressed in different tissues at different 
times during mammalian development and how these different forms affect HIP1 






Figure 2.1:  Amino acid sequence of the HIP1 ANTH domain and schematic 
diagram of the HIP1 domain structure.  The majority of the mouse ANTH domain is 
encoded by exons 3 to 5.  The amino acid sequence of the mouse ANTH domain 
(italicized, [14, 15]) and a few additional carboxyl amino acids are shown in the box 
above the schematic diagram of the full-length protein.  A line is drawn through the 
amino acids that are encoded by exons 3 to 5.  Residues in bold (K, K, KH, K) share 
homology with AP180 and epsin and are considered to be critical inositol lipid-binding 
residues.  The predicted protein product encoded by the Hip1
3-5
 allele is 10 kDa and is 
shown schematically below the full length HIP1 diagram.  The predicted protein product 





Figure 2.2: Tumorigenesis in MMTV-myc mice in the absence of HIP1. Percent 
tumor-free survival out to 5 weeks of age is shown for MMTV-Myc+ mice on various 





Figure 2.3: Breast tumorigenesis in the presence of the Hip1Δ3-5 allele.  





backgrounds.  Mice were dissected at one year of age, or earlier if a tumor was found.  
44% of Myc+;Hip1
Δ3-5/Δ3-5
 mice developed breast tumors, compared to none of the Myc+; 
Hip1
null/null
 mice.  51% of Myc+; Hip1
+/Δ3-5
 mice developed breast tumors, compared to 
19% of Myc+; Hip1
+/null
 mice.   
B.  None of the Hip1
+/null
 mice with tumors (N=3) exhibited metastasis of the breast 
tumors. 25% of Myc+;Hip1
Δ3-5/Δ3-5
 mice with tumors (N=8) and 26% of Myc+; Hip1
+/Δ3-5
 
mice with tumors (N=19) had metastasis of the breast tumors to organs including the 
lungs, liver, spleen and salivary gland.  
C. Multiple breast tumors and metastasis to lungs of a Myc+; Hip1
Δ3-5/Δ3-5
 mouse at 30 
weeks of age.   
D.  Metastasis of a breast tumor to the lungs of a Myc+;Hip1
+/Δ3-5







Figure 2.4: Tumor incidence in mice with Hip1Δ3-5 and Hip1null alleles. MMTV-





backgrounds and analyzed for tumor incidence. TRAMP mice that survived to 6 months 
of age were scored for gross prostate tumors. In each case the mice with the Δ3-5 allele 






Figure 2.5: TRAMP mice on different Hip1 mutant backgrounds. 
A. Survival curve of TRAMP mice in different Hip1 mutant backgrounds.  









Figure 2.6: Expression of Hip1 sequences in Hip1Δ3-5 mice.   
A.  Tumors from mice with breast (MMTV-myc) and prostate (TRAMP) cancer were 
grown in culture and analyzed by western blot for the presence of HIP1 polypeptides.  
Results from an MMTV-myc breast tumor sample are shown.  P=passage number. Even 
at zero passages (P0), the cultured cells from 3-5/ 3-5 tumors expressed a slightly 
truncated form of HIP1 (Lane 4).  This product was not detected in the bulk tumor tissue, 
in the normal tissues tested of these mice, or in any cell types derived from mice 
heterozygous for the Δ3-5 allele (lanes 5-10). 
B.  RT-PCR of total RNA extracted from 3-5 allele-containing tumor-derived cultured 
cells resulted in the generation of wild type (WT) and mutant ( 3-5) bands of expected 




C.  Partial Hip1Δ3-5 cDNA sequence alignment with wild type mouse Hip1 cDNA 
demonstrated an AG dinucleotide insertion between exons 2 and 6 of the Hip1 3-5 
cDNA sequence.  This insertion maintains the open reading frame of the transcript.  
Tumor cell line genomic DNA contains a recombined “AT-AC” intron. Genomic DNA 
isolated from a Myc breast tumor-derived cell line was sequenced in the region where the 
recombination occurred (box).  The sequence was compared to wild type Hip1 genomic 
DNA and no additional mutations were observed.  Note the recombinant intron flanked 
by exons 2 and 6 has a U12-dependent consensus branch point sequence (italicized) and a 
3’ AC dinucleotide (italicized) that serves as the cryptic splice site acceptor.  This 
splicing event results in an “AG insertion” in the transcript.  The region sequenced is 
indicated by the box that encompasses exons 2, 6 and intervening sequences including the 








Figure 2.7: Partial Hip1Δ3-5 cDNA sequence alignment with wild type mouse Hip1 
cDNA. Shown is an alignment of cDNA sequence from the nested PCR reaction with the 
exon 2/3 and exon 5/6 junctions of mouse Hip1 mRNA reference sequence 
(NM_146001). Dots in the mouse Hip1 mRNA reference sequence denote identity with 
the Hip1 Δ3-5 cDNA sequence. Codons are represented by alternating bold/nonbold 
trinucleotide sequences. Note the AG dinucleotide insertion between exons 2 and 6 of the 







Figure 2.8: Expression patterns of the 3-5insAG mRNA and its putative protein 
product.  
A.  Northern blot analysis using a probe specific for the 5’ end of the mouse Hip1 mRNA 
(nucleotides 1-1260) demonstrated the presence of a significant amount of a slightly 
truncated product in the RNA of mouse embryonic fibroblast (lane 2 versus lane 1).   
B.  Primers specific to the exon 1/2 junction (forward) and the exon 13/14 junction 
(reverse primer) of murine Hip1 cDNA were used to amplify the cDNA.  The resulting 
products were separated on a 1.0% agarose gel.  Water was used as the negative control 
(lane 1).  RNA from a TRAMP prostate cancer cell line generated from the prostate 
tumor tissue of a mouse that was heterozygous for the Hip1
Δ3-5
 allele was used as a 
positive control for both the wild type Hip1 and Hip1
Δ3-5/insAG
 mRNA transcripts (lane 2).  
A 1.6 kb band indicates the presence of wild type Hip1 mRNA transcripts while a 1.3 kb 
band indicates the presence of the mutant Hip1
Δ3-5/insAG
 mRNA transcripts.  Brain, lung 
and kidney tissues from wild type Hip1 mice (+/+) produced the 1.6 kb band but not a 1.3 
kb band (lanes 3, 6 and 9).  Similar tissues from heterozygous Δ3-5 mice (+/Δ) produced 
both a 1.6 kb band and a 1.3 kb band (lanes 4, 7 and 10).  Only the 1.3 kb band was 
produced in brain, lung, and kidney tissues from homozygous Δ3-5 mice (Δ/Δ) (lanes 5, 
8 and 11). 
C.  Expression of the truncated product was most prominent in lung tissue although lesser 
amounts are detected in all other tissues tested.  Interestingly, brain tissue from 3-5 
adult mice displayed significant amounts of a protein product that co-migrated with the 
wild type form.  This co-migration was not observed in the extracts from embryonic 
brains (described in panel D).  Actin blotting was performed using an anti-actin 
monoclonal antibody (Sigma) as a control.    
D.  Postnatal day zero brains (isolated immediately after birth) have HIP1 banding 
patterns similar to those of embryos.  Pre-weaning stage brains have two distinct HIP1 






Figure 2.9: HIP1 Δ3-5/insAG 106 kDa protein is present in mouse embryonic brain 
and fibroblasts. Western blot analysis for HIP1 expression in the brains (left panel) and 
fibroblasts (right panel) of 17-day old mouse embryos of different genotypes 
demonstrated the presence of a slightly truncated HIP1 product. MEF cells of different 
genotypes were cultured from eleven individual embryos from the same mother. Only 5 







Figure 2.10:  Conditional cre-mediated recombination of the floxed Hip1 allele leads 
to either HIP1 deficiency or expression of the truncated product depending on tissue 
analyzed.  
A.  Mx1-Cre transgenic mice carrying none (+//+; lanes 2 and 7), one (-/+; lanes 3 and 8) 
or two (-/-; lanes 4-6 and 9-11) of the floxed Hip1 alleles were treated with 3 injections of 
pIpC at 8-12 weeks of age then were retreated at 20 weeks of age.  Their organs were 
harvested at 28-32 weeks of age.  Organ extracts were separated on 6% SDS-PAGE and 
analyzed for HIP1 expression by western blotting (using the UM354 (1:5000) antibody). 
An extract of a wild type brain (lane 1) was included as a positive control of HIP1 
expression.  Near complete recombination (resulting in the deficiency of HIP1 protein) 
was observed in liver and kidney but not in thymus and spleen where residual wild type 
HIP1 and truncated HIP1 (putative 3-5insAG product) was expressed.  As expected, 
eye, brain, and heart tissue showed no evidence for recombination since Mx1-cre is not 
induced in these tissues [42].  A small amount of putative 3-5insAG truncated product 
was observed in lung tissue and may be a result of recombination in tissue macrophages, 
which are abundant in the lung tissue.   
B. Mice were untreated (lanes 1, 2, 9 and 10) or treated at 6 weeks of age with pIpC (6 
doses IP every other day; lanes 3-6 and Lanes 11-14).  A small group was treated with 
pIpC again at 20 weeks of age (3 additional doses every other day; lanes 7, 8 and 15, 16).  
The mice were sacrificed at 6 months of age, and their tissues were analyzed for HIP1 
expression by western blot (UM354).  Complete deficiency of HIP1 was never observed 
in bone marrow despite continued pIpC injections whereas complete deficiency of HIP1 
was achieved was maintained in the liver without repeated recombination.  Interestingly, 




truncated product in its cultured bone marrow (lane 6).   A small amount of the truncated 
product was observed in cultured bone marrow from some untreated mice (e.g. lane 1), a 
finding consistent with the possibility that the endogenous production of interferon (i.e. in 
response to viral infections) can activate Mx1-cre expression at low levels in mice in the 
absence of pIpC treatment.  As a loading control, actin blots were performed on 10% 
SDS-PAGE using a monoclonal anti-actin antibody (Sigma, St. Louis, MO).  
C.  Mice were treated with pIpC in two stages: first at 21 weeks of age (with 6 every 
other day doses) and second at 55 weeks of age (with 6 every other day doses).  Six 
treated mice (3 heterozygous and 3 homozygous) and 5 untreated mice were necropsied.  
At necropsy, a previously undetected liver tumor was discovered in a treated 
heterozygous mouse, and it was harvested for histological and protein expression 
analysis.  Increased amounts of truncated HIP1 expression were observed in the tumor 
tissue compared to surrounding “normal” liver tissue.  Since this was a heterozygous 









Figure 2.11: HIP1 3-5insAG association with clathrin, AP2, EGFR and lipids. 
A.  HEK 293T cells were transfected with EGFR and/or various HIP1 constructs.  
Cells were lysed 24 hours post-transfection and polyclonal anti-HIP1 (UM323) and anti-
EGFR antibodies were used for immunoprecipitation.  The immunoprecipitates were 
separated on 6% SDS-PAGE gels and transferred to nitrocellulose for western blot 
analysis using the indicated antibodies.  Lanes 1-4: whole cell lysates.  Lanes 5-8: Pre-
immune immunoprecipitates.  Lanes 9-12: anti-HIP1 immunoprecipitates.  Lanes 13-16: 
anti-EGFR immunoprecipitates.  Note the association of AP2, CHC, and EGFR with 
HIP1 is preserved despite deletion of sequences encoded by exons 3-5.  Interestingly, the 
anti-EGFR antibody did not co-precipitate wild type HIP1 (top panel, lane 14) but did co-
precipitate the HIP1Δ3-5 and HIP1ΔLD mutant proteins (top panel; lanes 15 and 16).   
B.  Schematic diagrams of GST-5’HIP1 and GST-5’HIP1/Δ3-5 fusion proteins are 
shown.  Expression of these fusion proteins in E. coli BL21 was induced by treatment 
with 0.1 mM IPTG.  The cells were pelleted and lysed, and the fusion proteins were 
purified from the resulting extracts using glutathione sepharose 4 beads.  Ten microliters 
of a 1:10 dilution of the purified GST-5’HIP1 and GST-5’HIP1/Δ3-5 fusion proteins 
were run on a 10% polyacrylamide gel and immunoblotted with an anti-GST antibody 
(1:5000) or an anti-HIP1 antibody (UM354-1:2000) to ensure reaction of the proteins by 
the respective antibodies and to confirm their purity.  Similar amounts were run on a 
separate 10% polyacrylamide gel along with various known concentrations of BSA, and 
the gel was Coomassie stained to estimate the concentrations of the purified fusion 




C.  Protein solutions containing 10 g of either purified GST-5’HIP1 or GST-5’HIP1/Δ3-
5 protein in TBST with 1% milk were incubated with PIP arrays (Echelon) containing 
various concentrations of different phosphoinositides.  As with the PIP strips, both GST-
5’HIP1 and GST-5’HIP1/Δ3-5 proteins bound preferentially to PtdIns(3)P.  Lipid-protein 
interactions were detected using a polyclonal anti-GST antibody (Cell Signaling 










Figure 2.12: Comparison of lipid binding specificity and relative affinity GST-
5’HIP1/Δ3-5 and GST-5’HIP1 using PIP strips. Protein solutions containing 10µg of 
either purified GST-5’HIP1 or GST-5’HIP1/Δ3-5 protein in TBST with 1% milk were 
incubated with PIP strips (Echelon) containing 15 different lipids at 100 pmol/spot. 
Lipid-protein interactions were detected using a polyclonal antibody (UM354) that 
recognizes both GST-5’HIP1 and GST-5’HIP1/Δ3-5 proteins. Both proteins bound 






ALTERNATIVE HIP1 TRANSCRIPTS IN MOUSE AND HUMAN CELLS MAY 
ENCODE DIFFERENT HIP1 ISOFORMS 
Summary 
Huntingtin Interacting Protein 1 (HIP1) is a clathrin binding protein that is 
necessary for the in vivo maintenance of a subset of normal and neoplastic cells.  Reports 
of the ability of HIP1 to induce or inhibit cell death are conflicting.  One possible 
explanation for this is that different isoforms of HIP1 are expressed and these isoforms 
have different effects on cellular survival.  Indeed, here we have identified a second Hip1 
mRNA that may encode a protein with potentially opposing effects on cellular survival 
than the originally characterized isoform.  The two mRNAs differ only in their starting 
exons, designated exons 1a and 1b.  The predicted protein products differ only slightly in 
their amino termini. However, an alternatively translated protein product is selectively 
produced by the exon1b-containing transcript, possibly the result of translational 
reinitiation. This product lacks the AP180 N-terminal homology (ANTH) domain and 
may induce apoptosis when exogenously expressed. Efforts are currently underway to 
determine if this is the case. 
Introduction 
HIP1 was originally identified as a protein that binds huntingtin, the protein 
whose gene is mutated in Huntington’s disease [1, 2].  Subsequently, it was found to have 
domains that bind clathrin, AP2 [18-21], inositol lipids [14-16] and actin [46].  Knockout 
of Hip1 alone [26, 37] or together with its only known relative, Hip1-related (Hip1r) 
[27], results in an adult mouse degenerative phenotype, which are rescued by 
heterologous expression of full-length HIP1 [28]. HIP1 was independently identified as 




from a chromosomal translocation in bone marrow cells of a patient with leukemia [10].  
Subsequently, HIP1 protein levels were found to be elevated in prostate, colon [9], breast 
[38], brain [5] and lymphoid [7] cancers and HIP1 expression in prostate cancer was 
prognostic [9].  Furthermore, HIP1 on its own transforms fibroblasts [38] and is 
necessary for prostate cancer progression in mice [6].  As a result of these data, it has 
been hypothesized that HIP1 is a novel type of oncogene that, when over-expressed, 
hijacks normal endocytic pathways to transform cells by increasing pro-growth and pro-
survival signals from multiple receptors in parallel [47].  
In contrast to its role in promoting cellular survival or growth, it has also been 
reported that HIP1 has pro-apoptotic functions that contribute to neurodegeneration [3, 
4].  These functions have variably been dependent upon caspase 8 [4] and caspase 9 
activation which is enhanced by the presence of the protein designated “HIP1 protein 
interactor” (HIPPI) [3].  Although, we have searched and not found any apoptotic activity 
upon exogenous expression of HIP1 in our laboratory using the same cells (293T), we 
have found that a mutant HIP1 construct that lacks the ANTH domain (HIP1/ ANTH) 
does induce apoptosis [9, 16].  Furthermore, it was recently reported that there are two 
alternative forms of Hip1 in Drosophila that have opposing roles in Notch-mediated 
neurogenesis and these forms are homologous to the full length HIP1 and the 
HIP1/ ANTH form [30].  We have also observed by immunoblot analysis the presence 
of multiple isoforms of HIP1 in mouse tissues extracts [34] as well as in monocytic bone 
marrow cells induced to differentiate into osteoclasts [7]. 
To investigate the possibility that different forms of HIP1 have different functions 
as reflected by their pro- or anti-survival activities, we analyzed mammalian tissues and 
cells for the presence of alternative Hip1 transcripts.  We report here that there are at least 
two distinct Hip1 mRNA transcripts that result from the use of alternative first exons and 
these transcripts may encode different protein products that have opposing pro- and anti-
apoptotic activities.  These data provide a possible explanation of prior data that appears 




Materials and Methods 
5’ Rapid Amplification of cDNA Ends (RACE) analysis 
5’ RACE analysis was performed using the GeneRacer™ kit (Invitrogen). All 
procedures were performed according to the manufacturer’s suggestions. Five (5) µg of 
total RNA isolated from mouse brain and spleen was used as starting material for 
analysis. PCR amplified products generated in the last step of the 5’RACE procedure 
were separated on a 1% agarose gel run in 0.5X TBE running buffer. Bands of interest 
were extracted from agarose using the QIAquick® Gel Extraction kit (Qiagen) according 
to manufacturer’s protocol. Purified cDNA was subcloned into the pCR® 4-TOPO® 
vector for sequencing. All sequencing was performed by the University of Michigan 
DNA sequencing core facility. Sequence analysis was performed using the UCSC BLAT 
Search Genome program (http://www.genome.ucsc.edu/cgi-bin/hgBlat)  
HIP1 expression constructs 
MycHis-tagged HIP1A construct (previously referred to as full-length HIP1), was 
generated as previously reported [16]. MycHis-tagged HIP1B construct was generated 
using reverse transcriptase PCR (RT-PCR) with HEK 293T cell RNA as the starting 
material. A 1.2Kb fragment was generated using the following primers: 5’-ATA AGA 
ATG CGA GAA ATG AAT TGA C-3’ (forward) and 5’-CAG TTC TGC CCG CAG 
GAA TTC ACA C-3’ (reverse). The resulting fragment was digested with NotI and 
EcoRI to generate overhangs at the 5’ and 3’ ends. This fragment was ligated into NotI 
and EcoRI-digested pcDNA3.1-HIP1A. To generate the various ATG mutant constructs, 
we used the QuickChange
® 
XL Multi-Site-Directed Mutagenesis kit (Stratagene). The 
primers used were designed using the suggested primer design program at the Stratagene 
website.  
Cell culture 
All cell lines were obtained from A.T.C.C. unless stated otherwise. The 293T cell 
line was maintained in Dulbecco’s Modified Eagle Medium High Glucose 1x (Gibco, 
Invitrogen - Cat. #11965) supplemented with 10% (v/v) fetal calf serum, 100 U/mL 
penicillin and 100 µg/mL streptomycin, at 37°C in a humidified
 
atmosphere 5% CO2/air.  
The RAW 264.7 cell line was maintained in Dulbecco’s Modified Eagle Medium High 




serum, 100 U/mL penicillin and 100 g/mL streptomycin, at 37°C in a humidified
 
atmosphere 5% CO2/air.    
Mouse embryo fibroblast establishment and culture 
MEFs were isolated and cultured as previously described [27].  Briefly, DKO 
MEFs were prepared from a total of 4 pregnancies and 10, 14, 16 and 18 day old embryos 
were used.  Following removal of the head and liver, embryos were rinsed several times 
with sterile phosphate buffered saline (PBS), minced with a scalpel and digested with 
trypsin (0.05% solution containing 0.53 mM EDTA) for 10 minutes at 37
o
C, using 1 ml 
of solution per embryo and shaking vigorously every 1 min.  The trypsin was inactivated 
by addition of DMEM supplemented with 10% FBS, 2 mM glutamine and plated 
repeatedly to generate lines [48].  Staining for phalloidin, transferrin update and PDGFβR 
half life were analyzed as described previously [27]. 
RAW cell differentiation 
RAW cell differentiation to RAW-OC was performed by adding human 
recombinant RANKL (Sigma) at a final concentration of 35ng/mL. Following treatment 
with RANKL, cells were allowed to incubate under normal culture conditions for a total 
of 6 days. Media was changed after the first three days and every day thereafter.     
DNA Transfections  
Transfections of 293T cell lines were performed in 6-well plates using 
SuperFect® Transfection Reagent (Qiagen) according to the manufacturer’s suggested 
protocol. Cells were plated in a six-well plate
 
(2 mL per well) at about 2 x 10
5
 cells/mL in 
triplicate and grown
 
for 24 h before transfection. Two µg of the various pcDNA 3.1 
expression constructs were transfected into cells.  
Quantitative real time-PCR (qPCR)   
Total RNA was isolated from cells and tissues using the RNeasy® RNA isolation 
kit (Qiagen). First strand cDNA for real time PCR was generated using the SuperScript 
First-Strand Synthesis System for RT-PCR kit (Invitrogen). Random hexamers were used 
for reverse transcription of cDNA. Concentration of resulting cDNA was quantified using 
a ND-4000 nanodrop spectrophotometer. Samples were diluted to a final concentration of 




performed in triplicate. The real time PCR reactions were performed using a 
Mastercycler ep realplex (Eppendorf) according to the manufacturer's instructions.
 
For 
relative expression calculations, expression values of target transcripts were normalized 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer efficiencies were 
determined prior to data analysis and these efficiencies were used to calculate relative 
expression using the Pfaffl method [49]. For determination of absolute transcript levels, a 
standard curve was generated individually for each transcript analyzed. Standard curves 
were generated using purified cDNA plasmids, which contained PCR-amplified inserts of 
each target transcript.  
The primers used were designed to generate amplicons in the range of 150 to 200 
bp with the exception of GAPDH primer (294bp). The primers used for each qPCR assay 
were as follows: GAPDH forward
 
primer sequence was 5'-CTG GTG CTG AGT ATG 
TCG TG-3' and reverse
 
primer sequence was 5'-CAG TCT TCT GAG TGG CAG TG-3'; 
Total HIP1 forward
 
primer sequence was 5'-GCT GGG GAG CCA CTG TCA T-3' and 
reverse
 
primer sequence was 5'-GGT TGG GGC TGT CCT TAT CA; HIP1A forward
 
primer sequence was 5'-GAG AGC TTC GAG CGG ACT CA-3' and reverse
 
primer 
sequence was GGC AGA ACT TCC AGC AGA GC-3'; HIP1B forward
 
primer sequence 
was 5'-CGG TCA TGG ATG TGA GCA AG-3' and reverse
 
primer sequence was 5'-GGC 
AGA ACT TCC AGC AGA GC-3'. 
Protein isolation and western blot analysis 
Cells were washed with PBS and lysed using 100μl lysis buffer (50 mM Tris 
pH7.4, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA, and 10% 
Glycerol) containing protease phosphatase inhibitors mixture [30 mM sodium 
pyrophosphate, 50 mM sodium flavide, 100 µM sodium orthovanadate and 5 complete 
EDTA-free mini tablets (Roche)]. Cells were incubated on ice for 10 and centrifuged at 
13,200 rpm for 15 min at 4°C. Supernatant was transferred to new tubes and protein 
concentrations were determined by Bradford assay (Bio-Rad). Forty μg of protein was 
loaded to 6% SDS-polyacrylamide Tris-glycine gels (SDS-PAGE) unless stated 
otherwise. Gels were electrotransferred onto nitrocellulose membranes and membranes 
were blocked for 1 hour in TBS-T containing 5% non fat milk. The resulting blocked 




antibody specific to the N-terminus (1:5,000, UM354), a rabbit polyclonal HIP1 antibody 
specific to the C-terminus (1:5,000; UM410) or a mouse monoclonal α-myc antibody 
(1:2000; Cell Signaling). The next day, membranes were washed 3 times in TBS-T for a 
total of 15 minutes and incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies at room temperature for 1 hour. Membranes were developed with a 
homemade enhanced chemiluminescence reagent (ECL). 
Results 
An alternative Hip1 transcript is identified in mouse cells 
Moores et al. recently reported two alternative Hip1 cDNA clones in Drosophila, 
which differed in their starting exons [30]. These transcripts were predicted to generate 
different protein products, one of which lacked the key ANTH domain necessary for lipid 
binding. To explore the possibility of alternative Hip1 transcripts in mammalian cells, we 
performed 5’RACE analysis on RNA isolated from mouse brain and spleen, two tissues 
known to express Hip1 [26].  Two transcripts were repeatedly identified that differed in 
their starting exons (Figure 3.1).  The first transcript (designated Hip1a) contained a 179-
nucleotide sequence starting exon (exon 1a) and was the expected transcript that has been 
used consistently by our laboratory [9].  The second transcript (designated Hip1b) 
contained a 151-nucleotide sequence starting exon (exon 1b) and was located 56Kb 
downstream of exon 1a, within the originally identified 84Kb murine intron. The 
predicted protein starting from the first ATG in the exon 1a transcript is 1,030 amino 
acids and in the exon 1b mRNA is 996 amino acids. 
Having identified these two distinct transcripts, we wondered whether one or the 
other predominated in different cell types.  To analyze the absolute levels of each 
transcript, we first generated a standard curve using purified cDNAs plasmids that 
encoded either exon 1a- or exon 1b-containing transcripts (Figure 3.2).  The standard 
curves were used to calculate the copy number of both transcripts present in multiple 
samples of undifferentiated RAW 264.7 cells. The absolute amount of the Hip1b 
transcript was 5-fold greater than Hip1a (Figure 3.3).  Next we analyzed the transcript 
levels in intact mouse tissues relative to undifferentiated RAW cells to get an idea of the 
expression levels of the different Hip1 transcripts in different tissues. The cortex, 




than Hip1b (Figure 3.4). Lung had the highest levels of Hip1a transcript as well as the 
largest difference between transcript expression levels with Hip1a levels over 15-fold 
higher than Hip1b. Interestingly, western blot analysis of tissue extracts taken from the 
same mice demonstrated a single slower migrating band in all of the tissues with varying 
intensities (Figure 3.5) compared to RAW cells lysates, which demonstrated two distinct 
bands of similar intensities.  The slower-migrating band may represent the larger isoform 
of the HIP1 doublet we have observed previously [7] while the faster-migrating of the 
two bands observed in RAW cells may represent the smaller isoform. It appears that the 
transcript levels in different mouse tissues correlated with the western blot as the Hip1a 
transcript, which predicts for a larger protein, predominates in the tissues and only a 
larger protein is detected by western blot. However, there is no data (i.e. mass 
spectrometry analysis) at this point that confirms this slower-migrating band is indeed the 
predicted product of the Hip1a transcript.  
Previously, we reported that Receptor Activator for NFκB Ligand (RANKL) 
stimulation of the RAW cells leads to increased expression of the larger isoform of HIP1 
after 6 days in culture (Figure 3.6 - insert and [7]). Given that expression of this larger 
isoform of the HIP1 doublet in mouse tissues appears to correlate with Hip1a transcript 
levels, we wondered whether this phenomenon was due to induction of Hip1a mRNA.  
To answer this question, we performed quantitative PCR on differentiated RAW cells and 
compared the levels of Hip1a and Hip1b in these cells to that of undifferentiated RAW 
cells maintained in culture for the same period of time (6 days).  We found that Hip1a 
transcript levels were 2-fold higher in differentiated RAW cells than in undifferentiated 
RAW cells cultured under the same conditions (Figure 3.7). This was not the case with 
Hip1b levels as they remained the same. These data further support the hypothesis that 
the Hip1a transcript generates the larger HIP1 isoform of the HIP1 doublet. 
Up to this point, we had observed alternative Hip1 transcript levels in 1) a single 
murine-derived cell line under normal culture conditions with our analysis of 
undifferentiated RAW cells, 2) normal murine tissues and 3) a cytokine-induced 
phenotypic change in a single murine-derived cell line with RANKL-stimulated RAW 
cells. To expand this list of conditions for which alternative Hip1 transcript levels were 




be immortalized using the standard 3T3 immortalization protocol established by Todaro 
and Green [50]. MEF cell lines provide a nice system to study your gene of interest in 
which immortalized cells can be compared to non-immortalized cells. Hence, we wanted 
to examine whether changes in the expression levels of either transcript occurred upon 
immortalization.  
To investigate whether alternative Hip1 transcript levels changed upon 
immortalization, we isolated RNA from non-immortalized (passage 5) and immortalized 
(beyond passage 30) MEFs and used it for qPCR analysis. We analyzed the RNA for 
copies of both alternative transcripts similar to the process with undifferentiated RAW 
cells. The expression levels of both transcripts varied across the board with some cell 
lines having many more copies of both alternative Hip1 transcripts than others. To better 
visualize the differences in transcript expression levels for all four cell lines, we analyzed 
the ratio of Hip1a to Hip1b. In three of the four cell lines that were analyzed, we 
observed ratios higher than 1 indicating the presence of more Hip1a than Hip1b (Figure 
3.8). This is in stark contrast to undifferentiated RAW cells, which expressed 5-fold more 
Hip1b transcript than Hip1a. However, after immortalization the ratio of Hip1a to Hip1b 
decreased significantly in two of the four cell lines. In all four cell lines, the ratio 
decreased below 1 indicating that the amount of Hip1b transcript exceeded that of Hip1a.  
This shift in favor of Hip1b transcript levels is interesting given that RAW cells (an 
immortalized, transformed cell line) also express more of the Hip1b transcript whereas 
intact mouse tissues express more of the Hip1a transcript.  
Hip1b transcript expressed in human cells as well 
Having discovered an alternative Hip1 transcript in mouse, we wondered if this 
transcript was expressed in human cells as well. Chopra et al. initially reported the 
presence of alternative transcripts in human brain as a result of alternative splicing [29]. 
However, the alternative transcripts were not well characterized and no subsequent work 
was done to expand on this finding. Therefore we decided to look for HIP1B expression 
in human cells. To accomplish this, we used the mouse Hip1b sequence to identify a 
homologous region in the human HIP1 locus. We identified a highly conserved 152-
nucleotide region and used the sequence in this region to generate primers for qPCR 




and used this RNA to determine the copy number of HIP1A and HIP1B. As with analysis 
of the transcript levels in undifferentiated RAW cells, we generated a standard curve 
using purified cDNA plasmids specific to the human transcripts (Figure 3.9). 
Surprisingly, we found that the levels of HIP1A and HIP1B were equivalent (Figure 
3.10).  
We next decided to examine whether other cell lines expressed the HIP1B 
transcript as well. We have previously reported that HIP1 is expressed at high levels in 
multiple epithelial-derived cancer cell lines [9]. Additionally, we have observed that two 
HIP1 isoforms are detected in varying amounts by western blot analysis in some cancer 
cell lines (unpublished data). For instance, the ovarian cancer cell line SKOV3, only the 
larger isoform is detected whereas in the colon cancer cell line UACC257 both isoforms 
are detected but the smaller isoform is more intense (Figure 3.11 – insert). To test 
whether there was a relationship between the different protein isoforms and alternative 
HIP1 transcript levels, we performed qPCR analysis on a small subset of cancer cell lines 
in which varied detection of the two isoforms was observed. In addition to the SKOV3 
and UACC257 cell lines, we analyzed the DU145 (prostate cancer) and MDA-MB435 
(breast cancer) cell lines. Similar levels of both HIP1 protein isoforms were detected in 
these two cell lines (Figure 3.11 – insert). HIP1B transcript was detected in all four cell 
lines (data not shown). However, unlike 293T cells that expressed equivalent levels of 
HIP1A and HIP1B transcripts, all four cancer cell lines analyzed expressed more HIP1B 
than HIP1A (data not shown). The results in the SKOV3 cell line were rather unexpected 
given only the larger-mass isoform was detected. We also observed that there appeared to 
be a correlation of the ratios of HIP1A to HIP1B with the ratios of the larger isoform to 
the smaller isoform on western blot. We decided to analyze the ratio of HIP1A to HIP1B 
transcript to see if this was in fact the case. We found that as the ratio of HIP1A to HIP1B 
decreased, so did the intensity of the larger-mass isoform relative to the smaller-mass 
isoform (Figure 3.11). As with the data presented earlier in this chapter regarding HIP1 
isoform expression in mouse (Figures 3.4 and 3.5), caution must be used in interpreting 
this data. While it appears to indicate a connection between the alternative HIP1 




confirmed by either transcript-specific knockdown to show loss of the predicted isoform 
or N-terminal protein sequence data to show the predicted isoform sequence. 
Mutational analysis demonstrates potential alternative translation initiation start 
sites in HIP1B transcript 
It is possible, based on our analysis of alternative HIP1 transcripts so far, that the 
HIP1A transcript encodes for the larger isoform of the HIP1 doublet in both mouse and 
human cells and the HIP1B transcript encodes for the smaller isoform. The open reading 
frame (ORF) for the HIP1A transcript in humans predicts a 1038-amino acid product with 
an approximate mass of 116 KDa while the ORF for the HIP1B transcript in humans 
predicts a 1003-amino acid product with an approximate mass of 113 KDa. With a 
difference in mass of only 3 KDa, it appeared unlikely that the lower-mass isoform was 
the predicted HIP1B product. Furthermore, the predicted HIP1B product retains a full 
ANTH domain, unlike the truncated isoform identified in Drosophila [30]. To determine 
the actual product produced by the HIP1B transcript, we generated a myc/His-tagged 
human HIP1B cDNA expression construct and transfected it into 293T cells. Twenty-four 
hours after transfection, we isolated protein lysates from transfected cells and ran them on 
a 6% SDS-PAGE gel. Western blot analysis of the samples revealed an intense band, 
which migrated slightly faster than the band produced by our previously generated 
HIP1A cDNA construct (Figure 3.12). Surprisingly, a second, faster-migrating product 
appeared in one of the two HIP1B-transfected samples probed with an α-myc antibody. 
To ensure that this product was not the result of proteolytic cleavage, we repeated the 
experiment and isolated protein directly from the cell dish using boiling Laemmli buffer 
(2% sodium dodecyl sulfate, 5% β-mercaptoethanol and 0.125M Tris HCl). Western blot 
analysis of these samples resembled the first experiment with a faster-migrating band 
observed in both HIP1B-transfected samples (data not shown). This band did not appear 
in any of the HIP1A-transfected samples we analyzed.  
We began to wonder if this second band observed in HIP1B-transfected samples 
was the result of an alternative translation start site. Alternative translation mechanisms 
in eukaryotes have been reported to occur by “leaky scanning” when the predicted start 
AUG is in a suboptimal context [51, 52]. Additionally, translation reinitiation is a 




encoding for a very small peptide allows the 40S ribosomal subunits to remain intact and 
continue to scan the transcript until it comes into contact with another AUG in an optimal 
context [51, 52]. This process often involves skipping an AUG codon in an optimal 
context. To determine whether this was the case with HIP1B, we examined the cDNA 
sequence for other ORFs both upstream and downstream of the predicted translation 
initiation site (TIS). We came across an upstream ORF consisting of only 8 codons 
(Figure 3.13), which fit the criteria for an upORF [52] suggesting that reinitiation was 
indeed a possibility. This was not the case with the HIP1A transcript as there were no 
upORFs (data not shown), which explains the lack of a second band in HIP1A-transfected 
samples. In terms of downstream ORFs, we identified three potential downstream AUGs: 
two within exon 4 and a third within exon 5 (Figure 3.13). Interestingly, the predicted 
products of two of these ORFs lacked the ANTH domain (Figure 3.14) and all had an 
approximate mass at least 14 KDa less than the predicted HIP1A product (Table 3.1). 
Any one of these predicted products could potentially be the lower HIP1 isoform of the 
observed HIP1 western blot doublet.  
We next decided to begin to test the hypothesis that the smaller isoform was the 
product of translation reinitiation from the HIP1B. To do this, we generated multiple 
mutant constructs via PCR mutagenesis using the original HIP1B construct as a template. 
We mutated thymidines to cytosines in each of the putative ATG initiation start sites in 
the HIP1B transcript in different combinations. For the first construct, we mutated the 
ATGs at positions 134 to 136 and 149 to 151 in exon 1b to generate a construct that could 
not initiate translation from exon 1b (designated T135/150C). We hypothesized that this 
mutant would not express the original predicted product we observed in our original 
western blots. A second mutant construct consisted of mutations in the AUGs at positions 
401 to 403 and 410 to 412 in exon 4 (designated T402/411C). Our final mutant construct 
consisted of a mutation in the ATG at positions 479 to 481 in exon 5 (designated T480C). 
We planned to use the final two mutants to determine which of the ATG start sites were 
responsible for the smaller isoform of the HIP1 doublet. Neither of the two ATG start 
sites in exon 4 was in the optimal surrounding context but the exon 5 ATG start site was 
in an optimal context. Therefore we hypothesized that the exon 5 ATG was the 




all three mutant constructs into 293T cells individually and isolated protein from the 
transfected cells 24 hours later. We subsequently analyzed the samples by western blot.  
As expected we did not detect a band corresponding to the larger isoform of the HIP1 
doublet in T135/150C-transfected cells (Figure 3.15). Additionally, we detected two 
faster-migrating bands, one of which appeared to correspond to the smaller isoform of the 
HIP1 doublet. It is possible that the slower-migrating band of the two represents a 
product translated from one of the exon 4 ATG start sites while the faster-migrating band 
represents a protein translated from the exon 5 ATG start site.  Surprisingly, only the 
expected slower-migrating band was detected in the T402/411C and T480C mutant-
transfected samples (Figure 3.15). The faster-migrating band which represents the 
smaller-mass isoform of the HIP1 doublet was not detected in the non-mutated HIP1B-
transfected sample as well. Our continued experiments with these HIP1B constructs 
revealed that the faster-migrating band is not readily detected 100% of the time as is 
evident from Figure 3.12.  This inconsistent expression of the smaller-mass isoform may 
be due to the fact that the HIP1B construct does not contain the complete 152-nucleotide 
sequence of exon 1b, hence it lacks the upORF. If reinitiation is the mechanism by which 
translation from the downstream AUGs in either exon 4 or exon 5 is possible, than one 
would predict that loss of the upORF decreases translation efficiency from these sites.  It 
would be interesting to see if inclusion of the 5’ sequence of exon 1b improves the 
translation efficiency of these downstream ORFs.  
Discussion 
In this study, we describe the characterization of an alternative HIP1 transcript 
that is expressed in both mouse and human cells. The alternative transcript (designated 
HIP1B) uses an alternative starting exon (exon 1b) from the original HIP1 transcript 
(HIP1A). This is the first known report of an alternative Hip1 transcript in mouse and a 
characterization of an initially reported alternative HIP1 transcript in humans [29]. This 
finding has the potential to help resolve conflicting reports of HIP1 and its role in cellular 
survival and tumorigenesis versus its role as a pro-apoptotic protein. We hypothesize that 
the two transcripts encode for two different HIP1 isoforms, which differ in their amino-
termini similar to a recent report of multiple isoforms in Drosophila [30]. In this report, 




contrasting effects on Notch-mediated neurogenesis when exogenously expressed in 
Drosophila. The newly discovered transcript we describe in this report potentially 
encodes for a HIP1 isoform that lacks the ANTH domain as well. This isoform could 
possibly induce apoptosis given our previous report in which a HIP1 mutant cDNA 
construct lacking the ANTH domain induced apoptosis in 293T cells [9].  
Our analysis of both Hip1 transcripts in mouse RAW cells demonstrated that 
Hip1b transcript levels exceed Hip1a approximately 5-fold. However, when we 
stimulated RAW 264.7 cells with RANKL to induce differentiation into osteoclast-like 
RAW-OC cells, we observed a 2-fold induction of the Hip1a transcript but no change in 
the Hip1b transcript. This data is consistent with previously observed data in which 
expression of the larger isoform of the HIP1 doublet is detected in primary bone marrow 
cells 14 days after stimulation and increases in RAW cells 6 days after stimulation with 
RANKL [7]. This is the first report of selective induction of a Hip1 transcript by 
stimulation with a cytokine. Both the RAW cell differentiation and the primary bone 
marrow cell differentiation models provide a useful tool for future study of Hip1 
transcriptional regulation, particularly Hip1a transcriptional regulation.  
Our observations in RAW cells also provide us with more insight into the HIP1 
doublet. Based on the changes in HIP1 expression following RANKL stimulation, it 
appears that that the Hip1a transcript encodes for the larger isoform of the HIP1 doublet. 
In addition to the observations in RAW cells, Hip1a expression levels were higher in 
most of the intact mouse tissues. This appears to correlate somewhat to expression of the 
HIP1 doublet as only the larger isoform was detected in the same mouse tissues. Both 
isoforms were detected in RAW cells and in equivalent amounts. It appears that 
translation of the encoded proteins does not occur in a linear manner. In other words, the 
transcript levels do not seem to correspond directly to the protein levels. Perhaps the 
expression levels of each isoform are regulated by a post-translational mechanism that 
depends on the ratio of both transcripts present. Indeed, when human cancer cell lines 
that express varying levels of both HIP1 isoforms were analyzed for their expression 
levels of HIP1A and HIP1B, HIP1 isoform expression appeared to correlate with the ratio 
of HIP1A to HIP1B. Basically, the greater the ratio of HIP1A to HIP1B, the higher the 




Another intriguing possibility that may explain the lack of corresponding 
transcript and protein levels comes in the form of translational regulation of HIP1 similar 
to the classic example of GCN4 in yeasts [53]. GCN4 mRNA contains four small ORFs 
upstream of the Gcn4p coding sequences. Deletion of these ORFs or mutations in their 
start codons increases GCN4 translation without changing mRNA levels [54]. Individual 
mutational analysis of the upORFs demonstrated that upORF1 acts as a positive 
regulatory element of Gcn4p induction under amino acid starvation conditions while 
upORFs 2, 3 and 4 act as negative regulatory elements [55]. GCN4 translation is 
regulated The HIP1B transcript contains an upORF, which could potentially act as a 
regulatory element allowing translation of the dORF in either exon 4 or exon 5 under 
certain conditions or in certain types of cells. This possibility should be investigated in 
future studies.  
It is also possible that the antibody used for western blot analysis of these mouse 
tissues has a weak affinity for the smaller isoform. Although the antibody used was 
generated against the C-terminus of HIP1, which is similar in both proteins, there could 
be conformational changes in the smaller isoform that render the epitope less accessible 
and only high levels of expression of the isoform can be detected. This could explain the 
apparent equivalent levels of both isoforms in undifferentiated RAW cells despite a 5-
fold difference in transcript levels. More work is needed to understand this phenomenon. 
One could make the argument for post-translational modification of the HIP1 
protein as a reasonable alternative explanation for the HIP1 doublet. The smaller band of 
the doublet may be modified by a mechanism such as phosphorylation or ubiquitinylation 
leading to detection of a larger band. However, this appears unlikely given the fact that 
only one band is detected in protein samples isolated from HIP1A-transfected 293T cells 
when using the α-myc antibody and this band appears to resemble the larger band of the 
doublet. Previous observations regarding protein samples from HIP1A-transfected 293T 
cells using different HIP1 antibodies produce similar results. 
We also observed that the Hip1a transcript is expressed at higher levels than the 
Hip1b transcript in non-immortalized MEFs. However, the expression levels seem to 
shift in favor of the Hip1b transcript upon immortalization. The ratio of Hip1a to Hip1b 




cell lines trending towards a shift in favor of Hip1b expression. I would hypothesize that 
a certain ratio of Hip1a to Hip1b must be maintained in certain cells in order for the 
expression of the larger isoform to occur. A decrease in the ratio of Hip1a to Hip1b may 
lead to a decrease in, or altogether loss of, expression of the larger isoform of the HIP1 
doublet. Furthermore a decrease or loss of expression of the larger isoform may 
contribute to susceptibility to immortalization. However, more data from multiple 
different cells must be collected before this hypothesis can be substantiated. 
Far more uncertain is the phenomenon that regarding expression of the smaller 
isoform of the HIP1 doublet. The smaller isoform of the HIP1 doublet may be the product 
of an alternative mechanism of translation known as reinitiation [51, 52]. In short, this 
mechanism involves the translation of a small open reading frame (ORF) upstream of a 
predicted translation initiation site (TIS). These small ORFs typically consist of no more 
than 30 codons with the smaller ORFs being more effective. Translation of this upstream 
ORF reduces the translation efficiency of the predicted TIS and allows for alternative 
translation of downstream ORFs. Additionally, the distance between the termination code 
of the upstream ORF and the downstream ORF affects the translation efficiency of the 
downstream ORF with larger distances equating to higher translation efficiencies. The 
HIP1B transcript meets these criteria. It has an upstream ORF of 8 codons with a fairly 
large distance between the termination code of the upstream ORF and the AUG codons in 
exons 4 and 5. This is not the case with the HIP1A transcript, which could explain why 
we have not observed additional bands in cells transfected with HIP1A cDNA.  
Indeed, when we mutated the ATG codons in exon 1b we were unable to detect 
the slower-migrating band originally observed in HIP1B-transfected cells but we did 
detect two faster-migrating bands. The bands are likely the products of translation 
initiated from AUG codons in both exon 4 and exon 5. Both bands appear to be similar to 
the smaller isoform of the HIP1 doublet detected endogenously in 293T cells but it is 
unclear which of the two bands corresponds to the smaller isoform. We also observed 
that the faster-migrating band is not always detected in HIP1B-transfected cells. This 
may be due to lower translation efficiency of the downstream ORF in the HIP1B 
construct as it was originally designed. The construct lacks most of the 5’ end of exon 1b, 




also possible that this smaller isoform is regulated in a manner similar to GCN4 as 
mentioned above and loss of the upORF affects proper regulation of translation from the 
dORF. Regardless of the potential mechanism involved, the data presented in this chapter 
suggest that the HIP1B transcript may be responsible for the smaller isoform of the HIP1 
doublet. Efforts involving selective siRNA-mediated knockdown of each transcript are 






Figure 3.1: Diagram of alternative Hip1 transcripts in mouse. 5’ RACE analysis was 
performed on RNA isolated from mouse brain and spleen. Analysis revealed two 
alternative Hip1 transcripts (termed Hip1a and Hip1b). The transcripts only differ in their 
initial exon. Exon 1a is 179 nucleotides long and exon 1b is 151 nucleotides long. 








Figure 3.2: Standard curve for mouse Hip1a and Hip1b transcript analysis. Purified 
cDNA plasmids containing a PCR-amplified insert of either Hip1a or Hip1b transcript 
were serially diluted ten-fold starting from a copy number of 1.10 x 10
8
 to generate a 
standard curve for determination of copy number in each sample. Five points were used 
for each curve. Primer efficiencies and R
2






Figure 3.3: Absolute Hip1 transcript levels in undifferentiated RAW cells. Total 
RNA was isolated from undifferentiated RAW cells cultured under normal conditions 
and used to generate cDNA for quantitative PCR analysis. Absolute transcript levels were 
calculated as indicated in Materials and Methods and normalized to the starting amount 
of RNA used. This graph is representative of 3 independent experiments. Error bars 






Figure 3.4: Relative Hip1a and Hip1b transcript levels in various mouse tissues. 
Total RNA was isolated from various mouse tissues as indicated in Materials and 
Methods. Five (5) µg of total RNA was used to generate cDNA for qPCR analysis. 
Expression levels were normalized to Gapdh. Values represent Hip1a expression levels 
relative to undifferentiated RAW cells. This graph is representative of 3 independent 








Figure 3.5: Western blot analysis of mouse tissues. Various tissues were isolated from 
6-week old mice and protein was isolated from these tissues as indicated in the Materials 
and Methods section. Protein lysates were run on a 6% SDS-PAGE gel and transferred to 
nitrocellulose membrane for western blot analysis. Samples were probed with a 






Figure 3.6: RAW cell differentiation into RAW-OC leads results in an induction of 
higher molecular weight protein. RAW 264.7 cells differentiate into osteoclast-like 
cells 6 days after treatment with RANKL. RAW cells were cultured under normal 
conditions for 6 days after treatment with 35ng/mL of human recombinant RANKL. 
Media was changed after 3 days in culture and then everyday thereafter. On the sixth day 
after treatment with RANKL, RAW cells were harvested and protein was isolated. 
Protein lysate was prepared as indicated in Materials and Methods. The polyclonal Hip1 




Figure 3.7: Relative Hip1 transcript levels in differentiated RAW-OC cells. RAW 
cells were cultured under normal conditions for 6 days after treatment with 35ng/mL of 
human recombinant RANKL. Media was changed after 3 days in culture and then 
everyday thereafter. On the sixth day after treatment with RANKL, RAW cells were 
harvested and total RNA was isolated as indicated in Materials and Methods. Five (5) µg 
of total RNA was used to generate cDNA for quantitative PCR analysis. Expression 
levels were normalized to Gapdh. Values represent fold induction relative to untreated 
RAW cells cultured for 6 days. This graph is representative of 3 independent 






Figure 3.8: Ratio of Hip1a to Hip1b transcript levels in immortalized and non-
immortalized mouse embryonic fibroblasts (MEFs). Total RNA was isolated from 
both immortalized (late passage) and non-immortalized (early passage) MEFs cultured as 
indicated in Materials and Methods. Eight hundred (800) ng of total RNA was used to 
generate cDNA for quantitative PCR analysis. Absolute transcript levels were calculated 
as indicated in Materials and Methods and normalized to the starting amount of RNA 
used. Values reflect the Hip1a copy number divided by the Hip1b copy number. This 







Figure 3.9: Standard curve for human HIP1A and HIP1B transcript analysis. 
Purified cDNA plasmids containing a PCR-amplified insert of either HIP1A or HIP1B 
transcript were serially diluted ten-fold starting from a copy number of 1.10 x 10
8
 to 
generate a standard curve for determination of copy number in each sample. Five points 
were used for each curve. Primer efficiencies and R
2
 values are provided to show the 





Figure 3.10: Absolute HIP1 transcript levels in HEK 293T cells. Total RNA was 
isolated from HEK 293T cells cultured under normal conditions and used to generate 
cDNA for quantitative PCR analysis. Absolute transcript levels were calculated as 
indicated in Materials and Methods and normalized to the starting amount of RNA used. 







Figure 3.11: Ratios of HIP1A to HIP1B in selected cancer cells lines. Cancer cell lines 
with different HIP1 expression profiles were selected for quantitative analysis of both 
HIP1A and HIP1B transcripts. Total RNA was obtained from the National Cancer 
Institute and 800 ng of total RNA was used to generate cDNA for quantitative PCR 
analysis. Absolute transcript levels were calculated as indicated in Materials and Methods 
and normalized to the starting amount of RNA used. Values reflect the HIP1A copy 
number divided by the HIP1B copy number. This graph is representative of 3 






Figure 3.12: Exogenous expression of HIP1B AUG mutants in HEK 293T cells. HEK 
293T cells were cultured under normal conditions and transfected with one of the 
indicated cDNA plasmids. Twenty-four hours after transfection, cells were harvested and 
protein was isolated using the procedures indicated in the Materials and Methods section. 
Proteins were run on a 6% SDS-PAGE gel and transferred to nitrocellulose membrane. 
Membranes were blotted overnight with the one of the following antibodies: 1) Hip1 
polyclonal antibody (UM354), 2) monoclonal α-myc antibody or polyclonal α-actin 








Figure 3.13: Putative open reading frames (ORFs) in HIP1B transcript. The 5’ 
portion of the human HIP1B transcript is displayed along with potential upstream and 
downstream ORFs. Translation initiation sites (TIS) are represented in bold font. Kozak 
sequences are underlined and bases at positions -3 and +4, the most essential positions, 
are in bold italics. Odd-numbered exons are shaded gray beginning with exon 1b. The 








Figure 3.14: Alignment of predicted protein sequences. The predicted protein 
sequences of HIP1A and HIP1B were aligned with the potential protein products 
translated from downstream translation start sites in exon 4 and exon 5. Note the key 
lipid-binding motif for the AP180 N-Terminal Homology domain (ANTH) is absent in 
exon 4 and exon 5 potential products. Gray-shaded sequence indicates conservation 
between at least two potential products. Black-shaded sequence indicates complete 











Figure 3:15: Western blot analysis of mutant Hip1b-transfected cells. HEK 293T 
cells were transfected with the indicated Hip1 cDNA plasmid. Twenty-four hours after 
transfection, cells were harvested and protein was isolated. Protein lysates were prepared 
as indicated in Materials and Methods and run on a 6% SDS-PAGE gel. Gels were 
transferred to nitrocellulose membrane and probed with α-myc antibody at a dilution of 
1:2000 overnight.  The next day, membranes were washed and probed with HRP-
conjugated mouse secondary antibody. Lane assignments – 1) vector; 2) HIP1B; 3) 
















ANALYSIS OF THE HIP1A PROMOTER 
Summary 
We have recently shown that two forms of Huntingtin Interacting Protein (HIP1) 
are expressed in both mouse and human cells. One form, HIP1A, has been studied 
extensively in the past and has been characterized as a clathrin binding protein involved 
in receptor trafficking. Additionally, HIP1 has been described as a pro-survival protein 
primarily on the basis of studies that have focused on the HIP1A isoform. Exogenous 
expression of HIP1A has been reported to transform fibroblasts and the mechanism 
believed to be responsible is stabilization of receptor tyrosine kinases such as epidermal 
growth factor (EGF) receptor and fibroblast growth factor (FGF) receptor 4. This poses 
the question: Is aberrant HIP1A expression observed in cancer linked to transcriptional 
de-regulation? To begin to answer this question, we have investigated a putative 
promoter sequence 5’ of exon 1a. Our investigation has uncovered multiple κB sites 
within the promoter. However, NF κB activation does not appear to have a direct effect 
on HIP1 transcription in the system used. 
Introduction 
The Huntingtin Interacting Protein (HIP1) gene is quite complex. The mouse 
Hip1 gene maps on chromosome 5 at position 5qG2 in humans, and covers over 139 Kb. 
The human gene maps to chromosome 7 at position 7q11.23 and covers over 204 Kb. 
Both genes contain disproportionately large first introns relative to the rest of the gene. 
Intron 1 of the human HIP1 gene comprises over 139 Kb (roughly 68% of the gene) 
while intron 1 of the mouse Hip1 gene consists of over 89 Kb (about 64%). The existence 
of such a large intron suggests the possibility of an alternative promoter leading to 




of 31 exons, which suggests the possibility of multiple HIP1 transcripts through 
alternative splicing. Large 3’ untranslated regions (3’ UTR) of over 6kb in both mouse 
and human suggest additional regulatory mechanisms. Given this data it appears that the 
HIP1 gene may be highly regulated at the transcriptional and post-transcriptional levels. 
Our lab recently reported the presence of a unique U12-dependent intron, which leads to 
a cryptic splicing event in genetically-modified mice that lack exons 3 through 5 [34]. 
Surprisingly, the resulting hypomorphic protein is only expressed in certain tissues 
despite the presence of the mRNA transcript in non-protein expressing tissues. Given this 
data it appears that the HIP1 gene may be highly regulated at the transcriptional and post-
transcriptional levels.  
To this point, we demonstrated in the previous chapter of this thesis that 
alternative HIP1 mRNA transcripts are expressed in both humans and mice. These 
transcripts differ only in their starting exons. One transcript (HIP1A) uses a 179-bp 
starting exon (exon 1a) and translates a predicted protein product of 1038 amino acids. A 
second transcript (HIP1B) uses a 152-bp starting exon and encodes for a protein of 1003 
amino acids. The HIP1B transcript appears to encode a protein that lacks much of the 
AP180 N-terminal homology (ANTH) domain. This includes studies done by our 
laboratory suggesting HIP1A protein possesses transforming abilities. Exogenous 
expression of HIP1A cDNA(previously referred to as full length HIP1) transforms 
fibroblasts [8]. The mechanism believed to be responsible for this transformation is 
stabilizing of epidermal growth factor (EGF) receptor [8, 16]. Additionally, we have 
reported elevated levels of HIP1 in multiple cancers including brain, breast, colon, 
prostate and lymphoid cancers [5, 7, 9]. The particular form of HIP1 elevated in these 
cancers was not determined nor was the mechanism responsible for elevated expression 
uncovered. 
This study poses the question: Is aberrant HIP1A expression linked to 
transcriptional de-regulation observed in cancer? To answer this question, we subcloned a 
958-bp sequence upstream of exon1a into the pGL3 luciferase reporter vector and have 
shown it has promoter activity. Additionally we have identified the minimal sequence 
required for optimal promoter activity. Further analysis of the promoter revealed multiple 




significance).  However, there does not appear to be a direct effect of NFκB activation on 
HIP1A transcription in this system. 
Materials and Methods  
HIP1 promoter constructs 
The numbering chosen considers as -1 the nucleotide preceding the translation 
start site (ATG) located in the first exon. A region corresponding to the HIP1A promoter 
(-917 to +148 bp) was originally amplified by PCR using primers containing adaptors 
and cloned into the pcDNA3 vector inside the EcoRI site. This fragment was then 
digested with SacI and EcoRV and ligated into the pGL3-basic vector (Promega) digested 
with SacI and SmaI. In order to delete the region +42 to +148, we used the 
QuickChange
® 
XL Site-Directed Mutagenesis kit (Stratagene) with phosphorylated 
primers surrounding the region to delete. The final product was termed the -917/+41 
promoter construct. The 5’ truncated promoter mutant constructs, with the exception of 
the -331/+41 construct and the -240/+41 construct, were amplified by PCR with primers 
containing adaptors, using the -917/+41 promoter construct as a DNA template, and 
cloned between MluI and BglII. The -331/+41 construct and the -240/+41 construct were 
obtained by deletion of the -487/+41 construct using the QuickChange
® 
XL Site-Directed 
Mutagenesis kit, and phosphorylated primers.  
Generation of the region of interest (ROI) deletion mutant was obtained by PCR 
amplification of a 218-bp fragment just 3’ of the region of interest and an XhoI site at its 
5’end. The primers used for this reaction were 5’-AAG CTC GAG TCT GGA AGA CTG 
GCA GAA CTC ACA-3’ (forward) and 5’-AGT ACC GGA ATG CCA AGC TTA CTT 
AGA T-3’ (reverse). The resulting PCR product was gel purified and the digested with 
XhoI to produce overhangs at both ends of the fragment. The -917/+41 promoter 
construct was digested with XhoI as well to remove the region of interest and additional 
3’ sequence and the XhoI-treated PCR fragment was ligated into the vector using T4 
ligase (Roche). The resulting ligation product was propagated using DH5  cells 
(Invitrogen). 
Mutagenesis of the NFκB site in the -331/+41 construct was performed with the 
QuickChange
® 




protocol, using the forward primer 5’-GGG CGG GCG GCG GCG CCG TCT TTC GAA 
G-3’ and the reverse primer 5’-GGG GCC CTC GGC TGC CCC CTT CGA AA-3’.  
The PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen). 
All the plasmids were prepared and purified using the QIAprep Spin Miniprep and 
HiSpeed Plasmid Maxi Kits (Qiagen), and sequencing analysis were performed by the 
University of Michigan DNA sequencing core, using an ABI model 3730 sequencer 
(Applied Biosystems). 
Promoter analysis of putative cis-acting elements 
The HIP1A promoter sequence was analyzed for putative cis-acting elements 
using the TFSEARCH program [56].  
Cell culture 
All cell lines were obtained from A.T.C.C. unless stated otherwise. The 293T cell 
line was maintained in Dulbecco’s Modified Eagle Medium High Glucose 1x (Gibco, 
Invitrogen - Cat. #11965) supplemented with 10% (v/v) fetal calf serum, 100 U/mL 
penicillin and 100 g/mL streptomycin, at 37°C in a humidified
 
atmosphere 5% CO2/air.  
The RAW 264.7 cell line was maintained in Dulbecco’s Modified Eagle Medium 
High Glucose 1x (Gibco, Invitrogen - Cat. #11995) supplemented with 10% (v/v) fetal 
calf serum, 100 U/mL penicillin and 100 g/mL streptomycin, at 37°C in a humidified
 
atmosphere 5% CO2/air.   
The K562 cell line was maintained in RPMI-1640 media with L-Gln 2mM 
(Cellgro – Cat#10-040-CM) supplemented with 10% (v/v) fetal calf serum, 100 U/mL 
penicillin and 100 g/mL streptomycin, at 37°C in a humidified
 
atmosphere 5% CO2/air. 
DNA Transfections  
Transfections of 293T, K562 and RAW264.7 cell lines were performed in 6-well 
plates using SuperFect® Transfection Reagent (Qiagen) according to the manufacturer’s 
suggested protocol. Cells were plated in a six-well plate
 
(2 mL per well) at about 2 x 10
5
 
cells/mL in triplicate and grown
 
for 24 h before transfection. Five hundred ng of the 
various pGL3 promoter constructs were transfected into cells along with 50ng of pRL-




κB repeat construct, 500ng of DNA was transfected into cells along with 50ng of pRL-
CMV.renilla construct.  
Reporter gene assay 
Reporter gene assays were performed using the Dual-Luciferase Reporter Assay 
System (Promega) with slight modification to manufacture’s protocol. Twenty four hours 
after transfection, cells were washed with PBS. Five hundred L of passive lysis buffer 
was added to each well and incubated at room temperature for 15 minutes. Cell lysates 
were collected and centrifuged at 13,200rpm for 30 seconds at 4
o
C. Ten L of each lysate 
was added to individual wells of a white, opaque 96-well plate (Corning-Costar). 
Luciferase activity was measured using a Veritas microplate luminometer (Turner 
Biosystems). Firefly luciferase activity readings were normalized to the Renilla luciferase 
activity readings.  
Induction of NFκB activity 
NFκB activity was induced in 293T cells using human recombinant TNF  
(Sigma) at a final concentration of 10ng/mL. Following treatment with TNF , cells were 
incubated under normal culture conditions for a total of 6 hours unless indicated 
otherwise.  
NFκB activity in RAW 264.7 cells was induced using human recombinant 
RANKL (Sigma) at a final concentration of 35ng/mL. Following treatment with RANKL, 
cells were incubated under normal culture conditions for a total of 6 hours.  
Quantitative real time-PCR (qPCR) 
The 293T cells used for NFκB induction analysis were cultured in 6-well plates, 
treated with 10ng/mL TNF  and allowed to incubate under normal culture conditions for 
the times indicated. Total RNA was isolated from 293T cells using the RNeasy® RNA 
isolation kit (Qiagen). First strand cDNA for real time PCR was generated using the 
SuperScript First-Strand Synthesis System for RT-PCR kit (Invitrogen). Random 
hexamers were used for reverse transcription of cDNA. Concentration of resulting cDNA 
was quantified using a ND-4000 nanodrop spectrophotometer. Samples were diluted to a 
final concentration of 100ng/ul. A total of 100 ng of cDNA was used for each reaction 




performed using a Mastercycler ep realplex (Eppendorf) according to the manufacturer's 
instructions.
 
The RNA content of samples compared by qPCR was normalized based
 
on 
the amplification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
The primers used were designed to generate amplicons in the range of 150 to 200 
bp with the exception of GAPDH primer (294bp). Primer efficiencies were determined 
prior to data analysis and these efficiencies were used to calculate relative expression 
using the Pfaffl method [49]. The primers used for each qPCR assay were as follows: 
GAPDH forward
 
primer sequence was 5'-CTG GTG CTG AGT ATG TCG TG-3' and 
reverse
 
primer sequence was 5'-CAG TCT TCT GAG TGG CAG TG-3'; HIP1A forward
 
primer sequence was 5'-GAG AGC TTC GAG CGG ACT CA-3' and reverse
 
primer 
sequence was 5’-GGC AGA ACT TCC AGC AGA GC-3'. 
Immunoblot analysis 
The 293T cells used for NFκB induction analysis were cultured in 6-well plates, 
treated with 10ng/mL TNF  and allowed to incubate under normal culture conditions for 
the times indicated. Cells were washed with PBS and lysed using 100μl lysis buffer (50 
mM Tris pH7.4, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA, and 
10% Glycerol) containing protease phosphatase inhibitors mixture [30 mM sodium 
pyrophosphate, 50 mM sodium flavide, 100 M sodium orthovanadate and 5 complete 
EDTA-free mini tablets (Roche)]. Cells were incubated on ice for 10 min and centrifuged 
at 13,200 rpm for 15 min at 4°C. Supernatant was transferred to new tubes and protein 
concentrations were determined by Bradford assay (Bio-Rad). Forty (40) μg of protein 
was loaded to 6% SDS-polyacrylamide Tris-glycine gels (SDS-PAGE). Gels were 
electrotransferred onto nitrocellulose membranes and membranes were blocked for 1 h in 
TBS-T containing 5% non fat milk. Membranes were then probed overnight at 4°C with 
either the mouse monoclonal HIP1 antibody (1:2000, 4B10) or the mouse monoclonal 
 antibody (1:10,000; Cell Signaling). The next day, membranes were washed 3 
times in TBS-T for a total of 15 minutes and incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies at room temperature for 1 hour. Membranes 





Minimal promoter identified for human HIP1A promoter 
The mechanisms involved in the transcriptional regulation of the HIP1 gene have 
not been studied. To understand more about HIP1A transcriptional regulation in 
particular, we subcloned a 958-base pair sequence, which includes 917 base pairs 
immediately 5’ of exon 1a along with the first 41 base pairs of exon 1a into the pGL3 
luciferase reporter gene construct. This segment was selected with the intent of analyzing 
a 950-base pair region 5’ of the predicted translation initiation site (TIS) of the HIP1A 
transcript. Analysis of this sequence demonstrated presence of a canonical CAAT box 
and absence of a TATA box indicating the likelihood that this sequence functions as a 
TATA-less promoter [57] (Figure 4.1). We transfected the newly generated HIP1A 
promoter (-917/+41) construct into 293T cells and checked for promoter activity. As 
expected, promoter activity of the -917/+41 fragment registered much higher than the 
pGL3 promoter-less vector (data not shown). Surprisingly, -917/+41 activity was also 
higher than that of the SV40-containing reporter construct (data not shown). These data 
confirm that the 958-base pair sequence cloned and identified here does function as a 
promoter. 
To determine the minimal amount of sequence necessary for optimal promoter 
activity, we generated a series of 5’ truncated promoter constructs via PCR mutagenesis 
using the -917/+41 construct as a template (Figure 4.2).  We transfected these constructs 
individually into 293T cells and measured luciferase activity 24 hours after transfection. 
Luciferase activity of the first four truncated promoter constructs was similar to the -
917/+41 construct (Figure 4.3). However, luciferase activity of the -107/+41 construct 
exhibited a significant drop in promoter activity. 
To confirm these results, we transfected either the -107/+41, the -917/+41 or the -
240/+41 construct into the K562 cell line. K562 cell line was established from the pleural 
effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast 
crises. This cell line is one of the few leukemia-derived cell lines that expressed high 
levels of the HIP1 protein [9]. Luciferase activity of the HIP1A promoter constructs in 




concluded that the minimal sequence necessary for optimal promoter activity consists of 
the sequence corresponding to bases -240 to +41.  
Importance of bases -240 to -108 examined 
Given the fact that promoter activity decreased substantially with the loss of bases 
-240 to -108, we wondered whether this “region of interest” (ROI) was necessary for 
promoter activity. We analyzed this region for homology using the University of 
California-Santa Cruz (UCSC) genome browser (http://genome.ucsc.edu/) and observed 
“moderate conservation” between 27 vertebrae species specifically in the sequence -181 
to -108 compared to the rest of the promoter (data not shown). We hypothesized that this 
region may be important for promoter activity. 
It is also possible that the decrease in promoter activity observed in the -107/+41 
promoter construct was due to a substantial loss of required promoter sequence for 
optimal activity to occur. This construct retained only 148 bp from the original promoter 
construct. Perhaps there are compensatory elements upstream of the ROI and loss of 
these elements in addition to the loss of the ROI leads to diminished promoter activity. 
To test the hypothesis that the ROI is important for promoter activity, we generated a 
deletion construct, which lacked bases -181 to -108 (Figure 4.5) and transfected it into 
both 293T and K562 cells. Twenty-four hours after transfection, we collected protein 
lysates and measured luciferase activity in the samples. We observed no significant 
difference in the luciferase activity of cells transfected with the deletion mutant construct 
when compared to the -917/+41 construct (Figure 4.6). Based on these results, we 
concluded that the region -181 to +41 is not essential to HIP1A promoter activity but 
rather loss of such a substantial portion of promoter sequence affects optimal promoter 
activity. 
Analysis of human Hip1 promoter reveals multiple κB sites 
Sequence analysis of the HIP1A promoter sequence also demonstrated four 
putative B binding sites (Figure 4.1).  This was particularly intriguing given that our lab 
has reported HIP1 overexpression in both Hodgkin’s disease and non-Hodgkin’s 
lymphoma [7]. More specifically, Reed-Sternberg cells, considered to be the neoplastic 




activation of NF B is a characteristic of these Reed-Sternberg cells [58]. Additionally, 
we reported a change in HIP1 protein expression levels [7] as well as a significant 
increase in Hip1a transcript levels (chapter 3 of this thesis) following RAW 264.7 cell 
differentiation into RAW-OC, an osteoclast-like cells. Since this differentiation process is 
initiated by the activation of the Receptor Activator of NF B (RANK) by its ligand, 
RANKL, the identification of these putative κB sites seemed to suggest a role of NF B in 
HIP1A transcriptional regulation.  
To test whether these putative binding sites were functional, we used two of the 5’ 
truncations of the -917/+41 construct (Figure 4.7). One of the constructs lacked the first 
two B site (-487/+41) and the other maintained only the B site at positions -10 to -1 (-
331/+41). This B site was 100% conserved between the mouse and human HIP1A 
promoter sequences (data not shown), thus it was predicted to be the most important. We 
transfected the -917/+41 construct (all 4 B sites), the -487/+41 promoter construct (3 B 
sites) and the -331/+41 promoter construct (only one B site) into 293T cells. Twenty-
four hours after transfection, cells received 10ng/ml of TNF  to induce NF B activity.  
Six hours later, the cells were harvested, protein lysates were collected and luciferase 
activity was measured. Luciferase activity of cells transfected with the -917/+41 construct 
and treated with TNF  was reduced compared to the luciferase activity of uninduced 
cells (Figure 4.8). Cells transfected with the -487/+41 and the -331/+41 promoter 
constructs and treated with TNF  exhibited the same pattern. A B-luciferase construct 
was used as a positive control for NF B activation and as expected, luciferase activity of 
293T cells transfected with this construct was highly elevated 6 hours after treatment 
with TNF Figure 4.8 - insert). This apparent repression of the human HIP1A promoter 
was unexpected given the increase in Hip1a transcript levels observed in differentiated 
RAW cells. To test whether this repression was real, we mutated the B site at positions -
10 to -1 in the -331/+41 construct (Figure 4.9). As stated earlier, this site is the most 
highly conserved of the 4 B sites. We selected the -331/+41 construct as a template 
because it lacked the other three B sites yet it still exhibited a similar decrease in 
promoter activity. The mutated construct was transfected into 293T cells and repression 




the non-mutated construct. Cells transfected with the mutated B construct experienced a 
similar reduction in promoter activity as the non-mutated promoter construct (Figure 
4.10). 
To confirm the results observed in 293T cells treated with TNF , we decided to 
analyze our reporter constructs in RAW cells induced with RANKL. This system seemed 
like a logical choice given that we observe an increase in Hip1a transcript in RAW cells 
in culture for 6 days following RANKL treatment (chapter 3). We transfected RAW cells 
with the non-mutated -331/+41 construct as well as the -331/+41 construct with the 
mutated kB site. Twenty-four hours later we treated cells with RANKL (35ng/mL) and 
incubated them in culture for a total of 6 days following RANKL treatment. 
Unfortunately, both firefly and Renilla luciferase activity (used as a transfection 
efficiency control) in all samples collected was similar to non-transfected cells, 
suggesting that the cells that remained in culture no longer expressed the transfected 
constructs. To circumvent this issue, we studied promoter responsiveness to NFκB short-
term in RAW cells by measuring luciferase activity 6 hours after treatment with RANKL 
(similar to 293T analysis). Luciferase activity in RAW cells following treatment with 
RANKL was essentially the same compared to non-treated RAW cells in both the non-
mutated and mutated -331/+41 constructs (Figure 4.11). In contrast, the κB positive 
control was significantly increased following RANKL treatment. The conflicting data 
obtained from the promoter analysis in RAW cells coupled with no difference in 
promoter activity between the mutated and non-mutated promoter constructs following 
NFκB induction led me to question whether the apparent repression observed in 293T 
cells was a true indication of HIP1A promoter responsiveness to NF B. To explore 
whether NF B activation plays a physiological role in HIP1A transcriptional regulation, 
we decided to measure the effect of NF B induction on HIP1A mRNA transcript levels. 
To do this, we treated 293T cells with TNF  and isolated RNA from these cells at 
various timepoints following induction. The isolated RNA was used to generate first-
strand cDNA for subsequent quantitative PCR analysis. Quantitative PCR analysis of 
these samples revealed no significant changes in the levels of HIP1A transcripts relative 




Additionally, HIP1 protein levels did not change as determined by western blot 
analysis (Figure 4.13). I B degradation was analyzed to confirm that NF B was activated 
and indeed it was. Taken together, this data suggests that NF B does not act directly on 
the HIP1A promoter.  
Discussion 
Despite the extensive work that has gone into analyzing the HIP1 protein, very 
little work has been invested in understanding the transcriptional regulation of the gene. 
In particular, no work has been done to decipher differences in regulation of alternative 
Hip1 transcripts.  This study attempted to gain more insight into transcriptional regulation 
of the HIP1A transcript primarily based on the hypothesis that this transcript may 
potentially be de-regulated in cancer. The hypothesis is grounded in the fact that only the 
HIP1A cDNA has been shown to transform cells [8] and lead to plasma cell neoplasms in 
vivo [7]. 
DNA sequence 5’ of the transcriptional start site of the HIP1A transcript was 
isolated to determine whether it functions as an adequate promoter. As expected, the 
sequence exhibited strong promoter activity exceeding activity of an SV40-driven 
reporter construct. Further analysis of this sequence revealed that the minimal amount of 
sequence required for this optimal promoter activity was bases -240 to +41. Bases -240 to 
-108 initially appeared to be necessary for promoter activity as loss of these bases led to a 
substantial loss of promoter activity. However, when bases -181 to -108 were removed 
from the original -917/+41 promoter construct, activity was essential similar to the 
unmodified form of the promoter. This data suggests these nucleotides are not necessary 
for optimal activity to occur. It’s possible that there are multiple regulatory cis-elements 
present in the promoter sequence that are compensatory in nature. Loss of some of the 
elements alone may not be enough to diminish promoter activity but their combined loss 
dramatically affects overall promoter activity. The minimal amount of promoter activity 
that remained in the -107/+41 promoter construct is likely to be due to the CAAT box 
present in this minimal sequence. It would be interesting to see whether mutation of this 




Analysis of the HIP1A promoter also revealed the presence of four putative κB 
binding sites. The presence of these sites was encouraging given the association of NFκB 
and lymphoid malignancies [59]. We have previously reported HIP1 overexpression in 
Hodgkin’s disease and non-Hodgkin’s lymphoma [7]. In particular, Reed-Sternberg cells 
stain positive for HIP1. Reed-Sternberg cells are considered the neoplastic cell in 
Hodgkin’s disease and they have constitutive NFκB activation [58]. We have also 
reported in chapter 3 of this thesis that Hip1a transcript levels are elevated in RAW cells 
following their treatment with RANKL. RANKL is a known inducer of the NFκB 
pathway. The effect of NFκB activity on HIP1A transcriptional regulation was explored 
using the luciferase reporter gene system and quantitative PCR analysis. Initially, it 
appeared that HIP1A promoter activity was repressed by the activation of NFκB in 293T 
cells as treatment with TNF led to a decrease in promoter activity. However, further 
analysis of promoter activity in RAW cells treated with RANKL showed no change. 
Additionally, there does not appear to be any direct physiologically significant response 
to activation of NFκB in 293T cells. Under the same induction conditions used for the 
reporter gene assay, essentially no changes in HIP1A transcript levels or HIP1 protein 
levels were detected. Taken together, these data suggest no involvement of the NFκB 
signaling pathway in HIP1A transcriptional regulation. These data also suggest that the 
induction of Hip1a transcript levels observed in differentiated RAW cells is unlikely a 
direct result of NFκB signaling on Hip1a transcriptional regulation. It is worth noting that 
the NFκB signaling cascade is not the only one activated with RANKL stimulation. There 
are at least four other signaling cascades that have been reportedly activated due to 
RANKL stimulation: 1) c-Jun N-terminal kinase (JNK), 2) p38, 3) extracellular signal-
regulated kinase (ERK) and 4) Src [60]. Preliminary analysis of the HIP1A promoter 
sequence did not reveal any response elements associated with these signaling pathways. 
However, this does not rule out the possibility of their involvement in Hip1a 
transcriptional regulation. More work must be done to determine the mechanisms 






Figure 4.1: Human HIP1A promoter sequence. The 917-base pair sequence 
immediately 5’ of exon 1a as well as the first 41 base pairs of exon 1a were PCR 
amplified and subcloned into the pGL3 Firefly luciferase reporter gene construct. 
Analysis of this sequence revealed the presence of 4 NFκB sites (shaded gray) and the 
typical CAAT box (underlined). The sequence is numbered with the transcription start 








Figure 4.2: Diagram of various promoter constructs. Multiple 5’ truncations of the 
original HIP1A promoter construct were generated in order to determine the minimal 







Figure 4.3: Human HIP1A promoter activity in 293T cells. The various promoter 
constructs were transfected into HEK 293T cells along with Renilla luciferase constructs 
(transfection efficiency control) and protein lysates were collected 24 hours after 
transfection in order to measure luciferase activity. Firefly luciferase readings were 
normalized to Renilla luciferase readings. This graph shows the fold increase of 







Figure 4.4: Human HIP1A promoter activity in both HEK 293T and K562 cells. 
Three of the promoter constructs were transfected into both HEK 293T cells and K562 
cells along with Renilla luciferase constructs (transfection efficiency control). Protein 
lysates were collected 24 hours after transfection in order to measure luciferase activity. 
Firefly luciferase readings were normalized to Renilla luciferase readings. This graph 
shows the fold increase of normalized luciferase activity compared to the promoter-less 








Figure 4.5: Diagram of the “region of interest” deletion mutant construct. The 
human HIP1A promoter sequence from -181 to -108 was deleted from the original 
promoter construct by PCR mutagenesis in order to analyze whether this region was 










Figure 4.6: Promoter activity of -181/-108 deletion mutant in HEK 293T and K562 
cells. Both the original promoter construct and the -181/-108 deletion mutant construct 
were transfected into HEK 293T and K562 cells along with Renilla luciferase constructs 
(transfection efficiency control). Protein lysates were collected 24 hours after transfection 
in order to measure luciferase activity. Firefly luciferase readings were normalized to 
Renilla luciferase readings. This graph shows the fold increase of normalized luciferase 








Figure 4.7: Diagram of promoter constructs with κB sites. A total of 4 κB sites (white 
bars) were identified through sequence analysis of the original promoter sequence. The -
487/+41 promoter construct contains 2 of the 4 κB sites and the -331/+41 promoter 
construct contains only one of the κB sites. This single κB site is the most conserved of 
the 4 (100% identical) when compared to mouse and very highly conserved among 








Figure 4.8: Human HIP1A promoter activity in HEK 293T cells following NFκB 
induction with TNF . The three promoter constructs identified in figure 4.7 were 
transfected into HEK 293T cells along with Renilla luciferase constructs (transfection 
efficiency control). Twenty-four (24) hours later cells were treated with 10ng/mL of 
human recombinant TNF  and protein lysates were collected 6 hours later in order to 
measure luciferase activity. Firefly luciferase readings were normalized to Renilla 
luciferase readings. Promoter activity of TNF-treated cells is represented as a percentage 
of the normalized promoter activity of untreated cells.  A κB-luciferase construct was 








Figure 4.9: Diagram of the NFκB mutant construct. The NFκB site in the -331/+41 







Figure 4.10: NFκB mutant promoter activity in HEK 293T cells following NFκB 
induction with TNF . Promoter activity of the -331/+41 promoter construct, which 
contains the highly conserved κB site, was compared to the κB mutant construct indicated 
in figure 4.9.  Both promoters were transfected into HEK 293T cells along with Renilla 
luciferase constructs (transfection efficiency control). Twenty-four (24) hours later cells 
were treated with 10ng/mL of human recombinant TNF  and protein lysates were 
collected 6 hours later in order to measure luciferase activity. Firefly luciferase readings 
were normalized to Renilla luciferase readings. Promoter activity of TNF-treated cells is 
represented as a percentage of the normalized promoter activity of untreated cells. A κB-






Figure 4.11: Human HIP1A promoter activity in RAW 264.7 cells following NFκB 
induction with RANKL. Promoter activity of the -331/+41 promoter construct, which 
contains the highly conserved κB site, was compared to the κB mutant construct indicated 
in Figure 4.9.  Both promoters were transfected into RAW 264.7 cells along with Renilla 
luciferase constructs (transfection efficiency control). Twenty-four (24) hours later cells 
were treated with 35ng/mL of human recombinant RANKL and protein lysates were 
collected 6 hours later in order to measure luciferase activity. Firefly luciferase readings 
were normalized to Renilla luciferase readings. Promoter activity of RANKL-treated 
cells is represented as a percentage of the normalized promoter activity of untreated cells. 







Figure 4.12: HIP1A transcript levels following NFκB induction. HEK 293T cells were 
treated with 10ng/mL of human recombinant TNF  and harvested at the various 
timepoints indicated. Five (5) ug of total RNA was isolated from the cells and used to 
generate cDNA for quantitative PCR analysis. Relative expression levels were 
determined as described in the Materials and Methods section. Values represent 







Figure 4.13: HIP1 protein levels following NFκB induction. HEK 293T cells were 
treated with 10ng/mL of human recombinant TNF  and harvested at the various 
timepoints indicated. Protein was isolated from the cells and western blot analysis was 
performed as described in Materials and Methods and run on a 6% SDS-PAGE gel. 









The major goal of this thesis project was to provide insight into the transcriptional 
and post-transcriptional regulation of the HIP1 gene. The previous three chapters 
describe the studies aimed at accomplishing this goal. This chapter summarizes the major 
conclusions drawn from these studies. 
Partially functional HIP1 product suggests multiple isoforms with separate cellular 
functions  
In chapter 2, we describe a novel form of HIP1 that is expressed in vivo as the 
result of a novel cryptic splicing event between a 5’ AT-AC intron (intron 2) and a 3’ 
GT-AG intron (intron 5). Our initial intent was to generate a “third generation” Hip1 
knockout mouse allele (the Hip1
3-5
) that does not provide the confounding issues 
associated with the previously generated spontaneous “null” allele [26] and could be 
conditionally deleted. We planned to use this mouse to extend our analysis of HIP1 
involvement in tumorigenesis [6]. We were surprised to find that Hip1
Δ3-5/ Δ3-5 
mice, when 
crossed with tumor prone mice, are equally, if not more, prone to the development of 
prostate and breast tumors than Hip1 wild type mice. Further analysis demonstrated that 
the tumor cells from the Hip1
Δ3-5/ Δ3-5 
genetic background expressed a truncated form of 
the HIP1 protein (HIP1 3-5insAG protein) as a result of the novel cryptic splicing event 
described above. Additionally, HIP1 3-5insAG protein is selectively expressed in brain 
and lung examined from Hip1
Δ3-5/ Δ3-5 
mice but not kidney or spleen. This type of cellular 
natural selection provides us with the first clue that multiple HIP1 isoforms may be 





The second clue comes from the observation that the resulting protein product 
from the Δ3-5 mice slightly rescues the phenotype observed in Hip1 single knockout 
mice [26]. While homozygous Δ3-5 mice still develop spinal defects and testicular 
degeneration, they do not develop cataracts. Furthermore, the Δ3-5 protein still binds 
lipids, clathrin, AP2 and EGFR. It is possible that the mutant protein expressed in 
homozygous mice is similar enough to the wildtype protein involved in normal endocytic 
functions that it can partially compensate. Similarly, we conclude that the HIP1 protein 
responsible for normal spinal and testicular development and/or maintenance cannot be 
generated in the Δ3-5 mice. As I will discuss later in this chapter, one of the HIP1 
isoforms observed may be the result of a downstream ATG translation initiation site in 
either exon 4 or exon 5. Both of these exons are absent in the truncated Hip1 3-5insAG 
mRNA transcript. This mutant mouse provides an intriguing model to study Hip1 gene 
regulation more extensively. 
Alternative transcripts may code for different isoforms 
The study described in chapter 3 explores the possibility of the use of alternative 
HIP1 transcripts for generation of HIP1 isoforms with different cellular functions. In this 
work we describe the discovery of an alternative HIP1 transcript (HIP1B) in mouse and 
human. This is the first report of an alternative Hip1 transcript in mouse and a more 
rigorous characterization of an initially reported alternative HIP1 transcript in human 
[29]. The alternative transcripts are expressed in varying amounts in different mouse 
cells. For instance, the newly identified Hip1b transcript is expressed more 
predominantly in RAW 264.7 cells cultured under normal conditions (by approximately 
5-fold). In contrast, the Hip1a transcript is predominantly expressed in intact mouse 
tissues and non-immortalized mouse embryonic fibroblasts (MEFs), with most tissues 
expressing more Hip1a than Hip1b.  The most dramatic difference in transcript levels 
was observed in lung, which had Hip1a levels 15-fold higher than Hip1b. 
Our analysis of these alternative transcripts has uncovered two situations in which 
original expression patterns change. The first situation involves stimulation of RAW cells 
with the cytokine, receptor activator of NFκB ligand (RANKL). RANKL stimulation of 




stimulation. During this process, the Hip1a transcript is selectively induced by 2-fold 
while Hip1b transcript levels remained unchanged. This selective induction correlates to 
an increase in expression of the larger-mass isoform of the HIP1 doublet previously 
reported [7]. This finding provides us with the first reported Hip1-inducible system for 
further analysis of Hip1 transcriptional analysis and protein expression.  In the second 
situation, the ratio of Hip1a transcript to Hip1b transcript decreases upon immortalization 
of (MEFs). This observation requires more detailed characterization before any definitive 
conclusions can be made but the possible implications for study of the role of HIP1  in 
immortalization and transformation are exciting. 
The alternative transcripts differ only in their starting exons but this difference 
allows for potential translation from a downstream open reading frame (dORF). We 
hypothesize that downstream translation occurs through an alternative translation 
mechanism known as reinitiation [51, 52]. Exon 1b of the HIP1B transcript contains a 
small upstream open reading frame (upORF) of 8 codons just upstream of the predicted 
translation initiation site (TIS) that encodes for a 1003-amino acid protein. The HIP1A 
transcript does not encode any upORFs. Reinitiation at downstream ATGs typically 
occurs because small upORFs allow the 40S ribosomal complex to occasionally skip 
ATG codons that are in an optimal context when close to the upORF and initiate 
translation at more dORF in an optimal context. A classic example of this type of 
alternative translation is seen with GCN4 in yeast in which four upORFs play a 
regulatory role [53-55]. We have shown through mutational analysis that a band similar 
in migration, by SDS-PAGE, to the smaller-mass isoform of the HIP1 doublet is detected 
when the exon 1b ATG codons are disrupted. It is not known which of the downstream 
ATGs are responsible for the product most similar in migration to the smaller isoform. It 
is possible that both are translated as we have occasionally observed a HIP1 triplet, 
although far less frequently.  
We also cannot say definitively that the smaller isoform is indeed a product of one 
of these dORFs. It is possible that the HIP1 doublet is the result of post-translational 
modification of a single HIP1 protein. HIP1 may be phosphorylated, ubiquitinylated or 
modified in some other fashion and the larger band of the HIP1 doublet may be the result 




detected in protein samples from HIP1A-transfected 293T cells when using α-myc 
antibody to detect the cDNA product. As of yet, we have not detected both bands in 
HIP1A-transfected 293T cells using α-myc antibody or a HIP1 antibody specific to 
human HIP1 protein. Our data seem to support the hypothesis that the HIP1B transcript 
may encode for a different HIP1 protein than HIP1A.  
The data presented in chapter 3 provide the first evidence that HIP1 isoforms with 
distinct cellular roles exist in humans and mice. The predicted products of the dORFs in 
HIP1B each lack the AP180 N-terminal homology (ANTH) domain, which is necessary 
for lipid binding [14-16]. We have previously shown that exogenous over-expression of 
HIP1 with a functional ANTH domain transforms fibroblasts [38] and heterologous 
expression of this form of HIP1 leads to plasma cell neoplasms in vivo [7]. In contrast, 
HIP1 than lacks the ANTH domain induces apoptosis [9]. Others have shown that 
alternative Hip1 transcripts are expressed in Drosophila and these transcripts encode for 
two different isoforms, one of which lacks the ANTH domain [30]. These different 
isoforms exhibit contrasting effects on Notch-mediated neurogenesis when exogenously 
expressed in Drosophila. Preliminary studies regarding exogenous expression of the 
HIP1A mutant with disrupted exon 1b ATG codons in HEK 293T cells suggest that the 
expressed products induce apoptosis.  
Transcriptional regulation of HIP1A is complex 
In chapter 4, I report the identification and characterization of the HIP1A 
promoter. Our analysis revealed that the minimal sequence required for optimal promoter 
activity includes bases -240 to +41 with +1 designated as the transcription start site 
(TSS). We observed a dramatic drop in promoter activity when bases -240 to -108 were 
deleted from a 5’ truncated promoter construct. Sequence analysis of this region (“region 
of interest” or ROI) demonstrated moderate conservation between 27 different species 
from bases -180 to -108. To determine if these bases were necessary for promoter 
activity, we deleted this region from the original HIP1A promoter construct and measured 
luciferase activity. Surprisingly, promoter activity was similar to the original promoter 
construct suggesting that this region is not necessary for promoter activity. Perhaps there 
are cis-acting elements 5’ of this region that can compensate for the loss of this region. 




dramatically reduced. Clearly there are elements 5’ of this sequence, which are necessary 
for optimal promoter activity. More work will be done to identify the putative cis-acting 
elements necessary for HIP1A transcription. 
My analysis of the HIP1A promoter sequence also revealed 4 putative κB sites. 
Aberrant NFκB activity has been tied to multiple lymphoid malignancies including 
Hodgkin’s disease [59]. We have previously reported that HIP1 expression is elevated in 
both Hodgkin’s disease and non-Hodgkin’s lymphoma [7]. Additionally, we observed 
induction of the Hip1a transcript (reported in chapter 3) and increased expression of the 
larger mass HIP1 isoform  [7] 6 days after RAW cells have been treated with RANKL, a 
known inducer of NFκB activity. Therefore, we examined whether the HIP1A promoter 
is regulated by NFκB. Promoter analysis in both 293T and RAW cells suggests that this 
is not the case. Promoter activity in 293T cells initially appeared to decrease after 
treatment with TNFα but a similar decrease in activity was observed when the most 
conserved κB site was mutated in the HIP1A promoter construct that lacked the other 3 
κB sites. No change was observed in promoter activity when RAW cells were treated 
with RANKL under the same conditions. Furthermore, no change was observed in HIP1A 
transcript levels or HIP1 protein levels in 293T cells after treatment with TNFα.  
These results were somewhat surprising given the observed increases in Hip1a 
transcript and the larger HIP1 protein isoform (which may be the translated product of the 
Hip1a transcript) in RAW cells treated with RANKL. However, it is worth noting that 
binding of RANKL to its receptor target, RANK, triggers multiple signaling cascades 
responsible for lineage commitment as well as osteoclast activation, survival, cytoskelatal 
rearrangement and motility [60, 61]. In addition to activation of the NFκB signaling 
pathway, at least four other signaling cascades are reportedly activated: 1) c-Jun N-
terminal kinase (JNK), 2) p38, 3) extracellular signal-regulated kinase (ERK) and 4) Src 
[61].  Any one of these signaling cascades could potential be involved in increased 
expression of Hip1a transcript. Future efforts will focus on identifying the mechanisms 
responsible the selective increase in Hip1a expression. 
The future of HIP1 
The work involved in this project has provided exciting new insight to the field of 




generated an allele that encodes for a mutant form of Hip1 lacking exons 3 through 5. 
Mice homozygous for this mutant allele can serve as a model for investigating tissue-
specific expression of HIP1 protein. These mice selectively express the mutant HIP1 
protein and expression of HIP1 in the brains of these mice changes throughout 
development. Additionally, the mutant mRNA is incapable of generating products from 
the exon 4 and exon 5 AUG start codons. If the smaller band of the HIP1 doublet is 
another HIP1 isoform than further analysis of these mice may provide valuable insight 
into regulation of this product.  
We have also identified a second HIP1 transcript in humans and mice. The 
preliminary data presented in this thesis suggests the possibility that the two HIP1 
transcripts may encode for two isoforms with distinct cellular roles. The obvious next 
step is to confirm that these transcripts do encode for the different forms of HIP1 
observed by western blot. This can be accomplished by N-terminal sequence of the two 
bands detected by western blot analysis. An alternative approach to confirming the 
connection between the two transcripts and their apparent products is selective siRNA 
knockdown of the individual HIP1 transcripts. If the transcripts do encode for the two 
isoforms then loss of HIP1A transcript should result in loss of the larger isoform and 
knockdown of the HIP1B transcript should result in the loss of the smaller isoform. This 
approach could also provide insight into the distinct functions of the two isoforms. I 
would predict that knockdown of the HIP1A transcript would lead to decreased cellular 
survival and increased sensitivity to cellular stress. Knockdown of the HIP1B transcript 
may lead to increased susceptibility to transformation because of a lack of the HIP1 form 
perceived to be involved in apoptosis. A more ambitious goal would be to generate 
mutant mice that lack expression of either transcript. We know from our experience with 
the delta 3-5 mice, that this will be difficult. However, if these mice were successfully 
generated the resulting phenotypes would no doubt be informative.  
In terms of transcriptional regulation of HIP1, we have only scratched the surface. 
We have a model for selective induction of Hip1a transcript in the RAW cell 
differentiation model. Although the data generated from this model and other systems we 
used in this thesis project do not support our hypothesis that the HIP1A promoter is 




worth investigating other signaling cascades activated by RANKL signaling. There are at 
least four other signaling cascades mentioned earlier in this chapter that can and should 
be explored. Future studies should focus on these signaling cascades individually to 
improve our understanding of HIP1A transcriptional regulation. Additionally, generating 
a stable RAW cell line that has the HIP1A promoter construct may be worth pursuing. 
This would allow for a more accurate analysis of the HIP1A promoter using our inducible 
model. 
Finally, we would like to answer the question, “Which of the two transcripts is 
elevated in cancer?” This is really a fascinating question and it’s ultimately why we do 
the work we do. It would be interesting to compare expression levels in normal tissue to 
that of tumor tissue and see if any notable changes are present. I would predict that 
HIP1A is elevated in cancer based on our previous observations that HIP1A cDNA 
transforms NIH3T3 fibroblasts [38]. Over-expression of HIP1A cDNA in vivo also leads 
to plasma cell neoplasms [7] although this phenomenon is a bit more complex due to 
random integration of the cDNA. If this is the case, targeted therapies can be designed for 
cancer that express high levels of HIP1 particularly prostate cancer. Such therapies may 
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